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1. Introduction 
1.1 Cancer and colorectal cancer 
1.1.1 The hallmark of cancer 
  Cancer is the second most common cause of death globally, and was responsible 
for 8.2 million deaths in 2012 1. Approximately 14 million new cases were diagnosed 
with cancer in the world in 2012 1. Cancer is a heterogeneous disease caused by 
mutations and epigenetic changes 2. Ten fundamental hallmark features common to 
most cancer cells were described by Hanahan and Weinberg 3, 4 (Figure 1.1):  
 
 
 
 
Figure 1.1 The hallmarks of cancer. Ten fundamental hallmark features acquired during 
tumor development. Figure from 
3
. 
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1.1.2 Colorectal cancer 
  Colorectal cancer (CRC) is the third most common cancer diagnosed and the fourth 
most common cancer cause of death globally 1. The progressive accumulation of 
genetic and epigenetic alterations results in the transformation from normal epithelial 
cells to colorectal adenocarcinomas 5. The molecular pathogenesis of colorectal 
cancer is heterogeneous. Three different mechanisms underlying CRC etiology, 
namely chromosomal instability (CIN), CpG island methylator phenotype (CIMP), and 
microsatellite instability (MSI), were described 6. A classification of the molecular 
mechanisms underlying the development of CRC may be useful for determining the 
treatment response of patients 7, 8. 
  Cancer develops in a stepwise manner and each step is associated with changes at 
the molecular level. A widely accepted model of colorectal cancer progression was 
proposed by Fearon and Vogelstein 9. Vogelstein and colleagues demonstrated that 
most colorectal cancers begin with mutations in the adenomatous polyposis coli (APC) 
gene. Subsequently, additional mutations of the RAS-pathway promote the transition 
from breakthrough phase to expansion phase (see also Figure 1.2). These two 
mutations lead to the abnormal proliferation and disordered cellular architecture that 
defines benign tumors 10. Subsequent mutations in SMAD4, TP53, PIK3CA, and 
FBXW7, enable colorectal cancer cells to invade normal tissues and grow in 
otherwise hostile environments; such cells are defined as malignant 10. However, so 
far no genetic alterations have been shown to be required to convert a malignant 
primary tumor into a metastatic lesion 10. Therefore, malignant tumor cells may 
already possess the capacity to metastasize 10.  
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Figure 1.2 Three Strikes to Cancer. Examples of the genetic alterations leading to four 
representative cancer types are shown. Each gene symbol denotes a pathway. For example, 
APC denotes the pathway regulated by APC. A “mutation” in a pathway can be achieved by 
genetic or epigenetic inactivation of both alleles of a tumor-suppressor gene or by genetic 
activation of an oncogene in that pathway. Pathogenic strains of human papillomavirus initiate 
the breakthrough phase by disabling both the TP53 and RB pathways. Legend and figure from 
10
. 
 
  Approximately 90% of all cancer-related deaths are caused by metastases 11. 
About one-fifth of CRC patients present with metastasis and after surgical treatment, 
30 to 50% develop metastasis 12, 13. In CRC, primary cancer cells spread via blood or 
lymph circulation to distant organs, such as the liver, peritoneum, lungs, bone and 
brain. The liver represents the most frequent site of CRC metastases. Approximately 
55% of CRC patients develop liver metastasis. 
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1.2 Epithelial-Mesenchymal Transition 
  Epithelial-Mesenchymal Transition (EMT) is a cellular program that is important for 
the formation of tissues and organs during embryonic development and during wound 
healing 14. During EMT, epithelial cells lose cell-cell adhesion and cell polarity and 
acquire properties of mesenchymal cells, such as enhanced migratory and invasive 
capacities.  
 
1.2.1 EMT in tumor progression 
  EMT not only occurs during embryonic development, but also is an essential 
element in tumor progression and metastasis 15. Cancer cells at the primary site 
acquire a mesenchymal phenotype, which allows them to invade surrounding tissues, 
intravasate into and extravasate from blood-vessels, and colonialize distant organs 
and tissues 15, 16 (Figure 1.3). After seeding, these cells switch back to an epithelial 
phenotype and proliferate to form metastases 15. The processes by which cells switch 
between epithelial and mesenchymal phenotypes are known as the 
epithelial-to-mesenchymal transition (EMT) and its counterpart, the 
mesenchymal-to-epithelial transition (MET) 17 (Figure 1.3). During metastasis 
formation, primary tumor cells accumulate genetic and epigenetic changes, which 
enable these to escape from the tumor mass and invade into surrounding tissue 18, 19. 
Alterations of gene expression in the tumor microenvironment may also contribute to 
this process 20, 21. In patient samples, EMT is observed in the invasive front of various 
tumor types, indicating that micro-environmental signals trigger and control EMT 22-24. 
EMT also contributes to tumor stemness, escape from senescence, evasion of the 
immune system, chemo-resistance as well as tumor relapse 19.  
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Figure 1.3 Role of EMT during cancer progression. In tumor cells, EMT transcription 
factors (EMT-TFs) may primarily redefine the epithelial status of the cell, potentially - but not 
necessarily - assigning stem cell (SC) characteristics to dedifferentiated tumor cells, or they 
may redefine resident genetically altered stem cells to be cancer stem cells (CSCs). The 
dissemination of tumor cells from the solid tumor and subsequent migration after breakdown of 
the basement membrane (BM) - the classical view of the role of EMT in cancer — can only be 
achieved when all component pathways of the network are activated and fully parallels the 
process that is seen in development: if the cancer cell has acquired the necessary genetic 
aberrations and receives the appropriate signals at the tumor-host interface, the cell is ready to 
move towards metastasis. At this point, the active contribution of the EMT-associated 
programme is probably to give survival signals and to maintain the mesenchymal status of the 
metastasizing cell. It is likely that EMT also has a role in parallel progression, in which tumor 
cells escape early and metastasis progresses in parallel to the primary tumor. EMT features 
may further promote resistance during tumor therapy, leading to recurrence and a poor 
prognosis. The degree of EMT during the different steps in cancer progression probably 
depends on the imbalance of several associated regulatory networks with activated oncogenic 
pathways. Legend and figure from 
25
. 
 
1.2.2 Regulation of EMT 
  Much effort has been devoted to understanding the regulatory mechanism of EMT. 
A number of distinct signaling pathways regulate EMT 14. The best studied regulatory 
network controlling EMT is the transcriptional control. EMT transcription factors 
(EMT-TFs) are up-regulated in many different tumors 15. EMT-TFs are central 
regulators of EMT 26, 27. The zinc-finger transcription factor SNAIL is the best studied 
TF that regulates EMT 28. The expression of SNAIL inversely correlates with the 
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expression of E-cadherin 26. Indeed, SNAIL directly binds to an E-box (CACCTG) in 
the promoter of CDH1 28. Peinado et al. also showed that the expression of SNAIL is 
associated with poor prognosis, tumor recurrence, and metastasis in breast 
carcinomas 26. The transfection factor ZEB (zinc finger E-box-binding homeobox 
protein) induces EMT and directly binds to an E-box of CDH1 29. The EMT 
transcription factor TWIST is also a key regulator of EMT 26. As described below in 
chapter 1.3.3, ZNF281 represents a new EMT-promoting transcription factor that 
participates in these regulatory networks 30. Moreover, the transfection factor STAT3 
that mediates EMT induced by the pro-inflammatory cytokine IL-6, and thereby 
promotes invasion and metastasis of CRC cell lines 31.  
  Some other epithelium-specific transcription factors, such as GRHL2, ELF3 and 
ELF5, are decreased during EMT and actively drive MET when overexpressed in 
mesenchymal cells. All these findings suggest the concept of a tightly controlled 
balance between the epithelial and the mesenchymal status 25. 
  Besides EMT-TFs, epigenetic changes also contribute to EMT 32. The epigenetic 
regulation of CDH1 promoter has been recognized as part of the program that results 
in EMT 33, 34. For example, it has been shown that the hyper-methylation of CDH1 
correlates with the expression of SNAIL 35 and that ZEB1 modifies chromatin at the 
CDH1 promoter via recruiting SIRT1 deacetylase 36.  
 
1.3 The p53/microRNA-34 axis in colorectal cancer 
1.3.1 The p53 tumor suppressor protein 
  TP53, which encodes the p53 protein, is one of the most frequently mutated genes 
in human cancers. It has been reported that more than 80% of CRCs show 
inactivation of TP53 by mutation 37. The p53 protein represents a transcription factor, 
that is activated by diverse cellular stresses, such as DNA damage, ribosomal stress, 
oncogene activation and lack of oxygen or other nutrients and exerts multiple tumor 
suppressive functions through regulating the expression of its target genes 38. For 
example, p53 promotes cell cycle arrest, senescence, and apoptosis 39, 40. Under 
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conditions of stress and damage, p53 suppresses tumorigenesis either by supporting 
the repair of cells or eliminating damaged cells that cannot be repaired 41.  
  Recently, microRNAs have been added to the list of p53 targets that mediate its 
tumor suppressive function 42. p53 regulates the expression of its target miRNAs by 
direct binding to their promoters, as shown for miR-34a/b/c, miR-200, miR-15a/16-1, 
miR-192/194/215, miR-145 and miR-107. Alternatively, p53 regulates the processing 
of miRNA precursors, which has been shown for miR-16-1, miR-145, and 
miR-199a-3p 43. p53 also directly controls the transcription of genes that are involved 
in canonical metastasis pathways 44. Therefore, loss the function of p53 promotes 
migratory and invasive properties 44, which allows tumor cells to invade into 
surrounding tissues, enter into circulation and extravasate into secondary sites 45. The 
suppression of metastasis by p53 is mediated via the inhibition of factors 46, 47, which 
initiate and maintain EMT programs 25. Numerous EMT-TFs are repressed by 
p53-induced miRNAs. In colorectal cancer, p53 negatively regulates EMT by 
suppressing the expression of SNAIL and ZEB1 48, 49. In addition, our lab recently 
showed that the zinc finger 281 protein (ZNF281) and the STAT3 pathway are 
integrated into the p53 regulatory network via miR-34a 30, 31. Despite abundant 
evidence showing that metastatic processes are repressed by p53, TP53 knockout 
mice tumors do not metastasize frequently or display invasive physiologic 
characteristics 50, 51, suggesting that p53 loss alone is not sufficient to drive invasive 
cellular migration in vivo.  
 
1.3.2 microRNAs and miR-34 family 
  microRNAs (miRNAs), a subset of non-coding RNAs, are ~22 nucleotides long, 
single-stranded RNAs that exert biological functions by repressing the translation of 
target protein-encoding genes 52. miRNAs were first discovered as regulators of 
development in the nematode Caenorhabditis elegans 53, 54. Afterward, thousands of 
miRNA genes have been identified in animal and plant genomes 55. miRNAs are 
involved in many human diseases 56 and participate in the regulation of almost every 
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cellular process, such as proliferation, cell cycle control, apoptosis, differentiation, 
angiogenesis, migration, metabolism, autophagy, and stemness 57-61. Currently, 
miRNAs are being tested as targets and therapeutics to combat diseases and 
infections 62, 63. 
  Since the first demonstration of an involvement of miRNAs in lymphomas in 2002 64, 
the role of miRNAs has been investigated in various tumor entities 65. Deregulation of 
miRNAs expression has been shown in all types of human cancer 66, 67. Various roles 
of miRNAs were shown in cancer development and progression 59. About 50% of 
annotated human miRNAs are located within fragile regions of chromosomes, which 
are frequently lost in various human cancers 68.  
  The miR-34a and miR-34b/c genes are directly activated by p53 69, 70. miR-34a is 
transcribed from a unique gene located on chromosome 1p36.22, which is commonly 
deleted in neuroblastoma 71, whereas miR-34b and miR-34c are encoded by a 
common host-gene located on chromosome 11q23.1. Interestingly, miR-34a and 
miR-34c have identical seed sequences, whereas the miR-34b seed sequence is 
similar, but not identical, suggesting that miR-34a and miR-34c share similar mRNA 
targets, whereas miR-34b targets might be slightly different from these. Moreover, 
miR-449a/b/c belongs to the miR-34 family as well due to similarities in the seed 
sequence. It is located in a highly conserved region within the second intron of the 
CDC20B gene on chromosome 5 72. The expression of miR-34 is also induced by the 
ETS family transcription factors ELK1 and Foxo3a, which bind to the promoter regions 
of miR-34a and miR-34b/c, respectively 73, 74. Moreover, all members of the miR-34 
family are frequently down-regulated by epigenetic silencing in many tumor types 75, 76. 
The promoter of miR-34 harbors a CpG island, which represents a site of 
hyper-methylation causing transcriptional silencing either through affecting the 
binding of transcription factors or by influencing the chromatin status.  
  In addition, it has been shown that the EMT-TFs SNAIL and ZEB1 repress miR-34a 
and miR-34b/c by directly binding to E-boxes in the miR-34 promoters 48. This 
repression may be converted into permanent silencing by CpG-methylation. In mice, 
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miR-34a is ubiquitously expressed, with highest levels in the brain and testes, 
whereas miR-34b and miR-34c are expressed mainly in brain, lungs, and testes 77, 78. 
Thus, miR-34a is expressed at higher levels than miR-34b/c in most tissues, except in 
lungs, where miR-34b and miR-34c are predominant. 
  Recently, it was shown that miR-34a/b/c has an important role in the response to 
chemotherapeutic agents 79 and may act as a tumor suppressor 80. The miR-34 family 
suppresses tumor growth and metastasis through targeting multiple oncogenic target 
mRNAs 79.  
  The roles of the miR-34 family identified in cell culture based analyses suggested 
that it can also suppress tumor formation in vivo 79. Accordingly, re-expression of 
miR-34a caused 20% to 83% inhibition of tumor growth in xenograft mouse models of 
lymphoma, prostate, pancreatic or non-small cell lung cancer, as well as melanoma, 
81-83. In 2013, MRX34, a liposome-based miR-34 mimic, the first cancer-targeted 
miRNA-based drug, was used in phase I clinical trial in patients with advanced 
hepatocellular carcinoma 82, 84. Furthermore, co-treatment with miR-34 mimics may 
enhance the beneficial effects of conventional cancer therapies. It has been shown 
that in various cancer models, that ectopic expression of miR-34a precursors 
attenuates chemo-resistance to different chemotherapeutic drugs 82. Besides, 
hyper-methylation of the miR-34a/b/c promoters is frequently found in different 
primary tumors and various cancer cell lines and causes a significant reduction of 
endogenous miR-34a/b/c levels 85-87. Thus, de-methylating drugs may lead to 
re-expression of miR-34a/b/c and facilitate anti-cancer therapies in the future. Indeed, 
treatment of prostate cancer patients with BioResponse 3/3'-Diindolylmethane 
(BR-DIM) prior to radical prostatectomy in a phase II clinical trial led to the 
re-expression of miR-34a, which resulted in repression and nuclear exclusion of its 
target, the androgen receptor 88, 89. Moreover, natural compounds, such as 
Resveratrol, Rhamnetin, Genistein, and difluorinated Curcumin (CDF), cause 
re-expression of miR-34a in tumors, thus could be an important focus for future 
anti-cancer research studies 79. Therefore, development of efficient delivery system 
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for miR-34 into tumors or re-expression of miR-34 may be an efficient strategy for 
anticancer therapy. 
 
1.3.3 The p53/miR-34 axis in tumor development 
  As described above, p53 directly regulates miRNA expression or regulates the 
processing of miRNA precursors, but is also thought to be repressed by several 
miRNAs 43. This thesis focuses on the function of the p53/miR-34 axis in colorectal 
cancer. The miR-34 family encodes the first miRNAs found to be directly activated by 
p53 and suppress tumor growth and metastasis 79. The p53/miR-34 axis and its 
targets are often connected through positive or negative feedback loops that either 
reinforce the p53/miR-34 signaling or suppress it. For example, MDM4 binds to p53 
and inhibits its transcriptional activity, but MDM4 is also a target of miR-34a 90, 91 
(Figure 1.4A). Therefore, p53, miR-34a and MDM4 form a positive feed-back loop. 
Interestingly, the expression of miR-34 family can also be regulated by c-Myc via a 
miR-34a/c-Myc/ARF/HDM2/p53 negative feedback loop 92 (Figure 1.4A). 
Furthermore, SIRT1, which represses p53 activity by deacetylation of the p53 protein, 
is a direct target of miR-34a 93 (Figure 1.4B). miR-34a also directly targets 
nicotinamide phosphoribosyltransferase (NAMPT) 94. In addition, a positive feedback 
loop was found between SIRT1 and MYC 95, 96. Therefore, by repressing the 
c-Myc/SIRT1 axis, miR-34 may represent a central mediator of cell cycle suppression 
by p53. Moreover, the p53/miR-34 axis has also been implicated in the regulation of 
EMT, invasion and migration processes. miR-34a directly targets and suppresses the 
EMT-TF SNAIL 48, 49, whereas SNAIL represses all members of the miR-34 family by 
directly binding to their promoters in CRC cell lines, thereby forming a 
double-negative feedback loop 48 (Figure 1.4C). Furthermore, p53 induces members 
of the miR-200 family 97, which also represent EMT-regulating miRNAs that suppress 
EMT by a similar double-negative feedback loop involving the EMT-TFs ZEB1 and 
ZEB2 98, 99. These miRNAs form two double-negative feedback loops with their targets 
SNAIL, ZEB1, and ZEB2 that act as bimodal switches to stabilize either the epithelial 
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or the mesenchymal state 48. Moreover, ZEB1 was shown to repress miR-34a by 
binding to the same E-boxes in miR-34 promoters as SNAIL, thereby adding more 
complexity and further connecting the miR-34/SNAIL and miR-200/ZEB loops 48. 
Hahn et al. recently showed that the zinc finger 281 protein (ZNF281) is an important 
miR-34 target with respect to EMT 30. SNAIL and ZNF281 were directly targeted by 
miR-34a, which is repressed by SNAIL and ZNF281 30, 48, 100. Thereby, these factors 
form a negative feedback loop. 
  Recently, we found that exposure to pro-inflammatory cytokine interleukin-6 (IL-6) 
results in repression of miR-34a via direct binding of STAT3 to the promoter 
of miR-34a 31. Furthermore, miR-34 directly targets IL-6 receptor (IL-6R), which 
together forms an IL-6R/STAT3/miR-34a feedback loop (Figure 1.4D). The activation 
of this loop is required for EMT, invasion, and metastasis of CRC cell lines and is 
associated with nodal and distant metastasis in CRC patients. In addition, 
deregulation of this regulatory loop by deletion of miR-34a was shown to promote 
invasion in a mouse model of colitis-associated-colon cancer 31. 
  Among other direct miR-34a targets that promote cancer cell EMT, invasion and 
migration are c-kit 101, the RAS-oncogene homolog RRAS 102, Axl 103, Arhgap1 104, 
PDGFR-α/β 105, Fra-1 106, 107, and c-Met 108.  
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Figure 1.4 The role of p53/miR-34 axis in (A) p53 autoregulation, (B) cancer cell 
metabolism, (C) invasion and metastasis, (D) cancer-associated inflammatory signaling. 
Modified from 
43, 79
. 
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1.4 Hypoxia and cancer 
  The tumor microenvironment promotes cell proliferation, motility, and adhesion 109. 
However, the normal cellular microenvironment by suppresses malignant cell growth 
109. Hypoxia, i.e. low oxygen concentration, is an essential aspect of tumor 
microenvironment. Hypoxia is a hallmark of tumors caused by their insufficient 
vascularization 110. Also human colorectal carcinomas (CRC) display hypoxic areas 111. 
Clinically, hypoxia is associated with tumor progression, resistance to chemotherapy 
and radiotherapy and poor clinical prognosis 112-114. 
  The definition of hypoxia depends on the type of tissue and tumor that is studied 115. 
However, it is generally accepted that hypoxic tumors exhibit median oxygen levels 
below 2% 115. The phenotypic variability of cancer cells is partially related to their 
oxygen requirement and tolerance towards hypoxia 115. Cancer cells undergo genetic 
and epigenetic changes that allow them to survive in the hypoxic microenvironment 116. 
Cancer cells exposed to hypoxia display an elevated mutation frequency 117. And 
hypoxia was shown to promote chromosomal rearrangements, gene amplification, 
and reintegration into chromosomal fragile sites 118, 119. This accelerated genetic 
instability may lead to an aggressive, invasive and metastatic phenotype 120. In 
addition, mutation of the tumor suppressor TP53 provides cancer cells with a selective 
advantage under conditions of hypoxia 121. Indeed, hypoxia may influence most the 
hallmarks of tumorigenesis 122 (Figure 1.4).   
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Figure 1.4 The effects of hypoxia on the hallmarks of human cancers. Modified from 
3, 123
.  
 
1.4.1 The role of HIF transcription factors in cancer 
  HIF (hypoxia inducible factor) transcription factors belong to the basic helix–loop–
helix-PER-ARNT-SIM (bHLH-PAS) family and represent important mediators of the 
transcriptional response to hypoxia 124-126. HIF1A, which was first identified in studies 
of the human EPO gene 127, is a heterodimer consisting of an O2-regulated HIF1A 
subunit and a constitutively expressed HIF1B subunit. HIF1 binds to the 
hypoxia-response element (HRE), a consensus sequence 5'-RCGTG-3' in the 
promoter region of its target genes. HIF1A protein levels increase dramatically when 
the cellular O2 concentration is reduced 
128. HIF1A protein stability is negatively 
regulated by O2-dependent prolyl-hydroxylation, which enables binding of E3 ubiquitin 
ligase von-Hippel–Lindau (VHL), leading to ubiquitination and thereby proteasomal 
degradation of HIF1A. Elevated levels of HIF1A protein have been associated with 
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progression and poor clinical outcome for many different tumor entities 125, 129 
including CRC 130, 131. 
  HIF1A directly regulates genes that are related to the regulation of multiple adaptive 
responses to hypoxia 124, 132. HIF1A induces EMT through regulating EMT-TFs, 
activating EMT-associated signaling pathways, modulating EMT-associated 
inflammatory cytokines, as well as by influencing epigenetic regulators 133. Dependent 
on the cellular contexts, hypoxia induces a set of miRNAs, such as miR-21, 23, 24, 26, 
103/107, 210 and 373. miR-210 is directly induced by HIF1A and HIF1A is a direct 
target of miR-210 134. Therefore, these factors form a negative feed-back loop. 
Moreover, a large number of miRNAs are down-regulated under hypoxia 135. For 
example, miR-16-1, which is a prototypical tumor suppressor miRNA in leukemia and 
lymphoma, is down-regulated by HIF1A, and thereby contributes to the 
overexpression of VEGF in anaplastic large-cell lymphomas 136.  
  Initial work suggested that hypoxia has a minimal effect on the miRNA processing 
machinery 137, but more recent evidence suggests that hypoxia regulates miRNA 
processing. Several components of the microRNA processing machinery, such as 
Exportin 5 and AGO2, have been found to be regulated by hypoxia 138. In addition, 
hypoxia potentiates miRNA-mediated gene silencing through post-translational 
modification of AGO2 139. Very recently, EGFR was shown to suppress the maturation 
of specific tumor suppressive miRNAs in response to hypoxic stress through 
phosphorylation of AGO2. The association between EGFR and AGO2 was enhanced 
by hypoxia, leading to a reduction in the binding of Dicer to AGO2 and the inhibition of 
the processing from precursor to mature miRNAs 140. In breast cancer, Dicer was 
significantly reduced in a HIF-hydroxylase PHD2 dependent manner when exposed to 
hypoxia 141. In addition, hypoxia promotes stem cell phenotypes and poor prognosis 
through epigenetic regulation of DICER 142. Moreover, hypoxia-mediated 
down-regulation of the microRNA processing component Drosha is dependent on 
ETS1/ELK1 transcription factors 142. 
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1.4.2 Hypoxia and the p53 family 
  Hypoxia activates p53 via the activation of ATM (ataxia-telangiectasia mutated) or 
ataxia-telangiectasia mutated and Rad3-related kinases 143-145, PNUTS 146, 
mitochondrial generation of reactive oxygen species (ROS) 147 or enhancement of 
translation and mRNA half-life 148. Moreover, activation of p53 by hypoxia acts as a 
selective pressure during tumor growth, which results in the clonal expansion of cells 
with mutant or inactive p53 121. This mechanism may explain the more aggressive 
nature of hypoxic tumors and the frequent occurrence of p53 mutations in advanced 
stages of tumor development. However, the nature and function of p53 targets that 
are affected by loss of p53 function is largely unknown. Moreover, p53 represses the 
activation of HIF1-dependent signaling 149. The amplification of HIF1-dependent 
responses to hypoxia via loss of p53 contributes to the angiogenic switch, promoting 
cancer progression 150. Accordingly, p53-deficient tumors exhibit a poor response to 
combinations of anti-angiogenic treatments and chemotherapy 151.  
  Changes in HIFs and p53 activity allow cancer cells to survive through affecting 
angiogenesis, tumor microenvironment, metabolism, stemness, metastasis and 
recurrence 152. For example, the transcriptional reprogramming mediated by HIF1 
modulates the expression of genes involved in ECM degradation within the primary 
tissues and at distant sites of metastasis 152. Loss or mutant p53 affects the ability of 
invasion and metastasis 153. Remarkably, the interaction of mutant p53 with TAp63 
promotes the stability of HIF, resulting in enhanced metastatic potential 154, 155. 
Therefore, altered interactions within the p53 family affect the activation of HIF 
signaling, thus facilitates HIF-dependent pro-metastatic activities 152. 
  The p53-miRNA network has been extensively examined in the context of 
oncogenesis and tumor biology 156. Recent work indicates that p53 may also regulate 
specific miRNA transcription during hypoxia independent of HIF signaling. Under 
hypoxic conditions (0.5% O2), p53 accumulates in aryl hydrocarbon nuclear 
translocator (ARNT) knockout mouse embryonic fibroblasts (MEFs) that lack intact 
HIF signaling and directly induces miR-210 157. The p53-mediated expression of 
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miR-210 protects cardiomyocytes exposed to hypoxia 157. Notably, p53 also induces 
other miRNAs, such as miR-107 and miR-192, during tumorigenesis that have also 
been implicated as hypoxia-regulated miRNAs 156. However, direct experimental 
evidence demonstrating a functional link between p53 and induction of these miRNAs 
in the context of hypoxia is currently lacking 158.  
 
1.4.3 Hypoxia and STAT3 
Hypoxia activates the transcription factor STAT3 via phosphorylation of STAT3 at 
serine 727 (S727) and tyrosine 705 (Tyr705) residues 159. Phosphorylation at S727 is 
required for the maximal transcriptional activity of STAT3 160, and has been implicated 
in the promotion of tumor growth and invasion 161-163. Furthermore, the activation of 
STAT3 by S727 phosphorylation was observed in various human cancer stem cells 
and is associated with poor overall survival 164. Interestingly, protein phosphatase 
1/PP1, which negatively regulates STAT3 by de-phosphorylation of S727, is inhibited 
by hypoxia 165. Phosphorylation of STAT3 at S727 is sufficient to activate STAT3 and 
enhances prostate tumorigenesis independent of Y705 phosphorylation 163, 166.  
 
1.4.4 Hypoxia and chemo-resistance 
  Hypoxia induces chemo-resistance to Cisplatin, 5-fluoro-uracil, Doxorubicin, 
Etoposide, Gemcitabine, Melphalan, and Docetaxel in various types of tumors 167. 
Also in colorectal cancer hypoxia induces chemo-resistance to 5-fluoro-uracil 168. 
Notably, HIF1A represents the main mediator of hypoxia-induced chemo-resistance 
167. Accordingly, inhibition of HIF1A reverses multidrug resistance in colon cancer 169 
and tumor cells expressing HIF1A are more resistant to Cytostatics than 
HIF1A-defective cells 170. HIF1A may mediate chemo-resistance via affecting drug 
transporters, drug targets or via changing the response to drugs 167. However, there 
are also HIF1A-independent mechanisms of hypoxia-induced chemo-resistance, such 
as acidosis and nutrient starvation, which inhibit cell proliferation and increase 
interstitial fluid pressure 171-173. Recently, several studies suggested that EMT plays a 
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central role in chemo-resistance by enhancing cancer cell survival, cell fate transition, 
and the induction of drug resistance-mediating factors 174-176. Some studies showed 
that hypoxia-induced EMT and chemo-resistance are frequently associated in diverse 
types of cancer 177-179. 
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2. Aims of the study 
The present study had the following aims: 
 Characterization of the role of the p53/miR-34a pathway in hypoxia-mediated 
effects during CRC progression 
 Characterization of miR-34a targets relevant for hypoxia-induced EMT in CRC 
cells 
 Determination of the prognostic and therapeutic value of the identified regulations 
and components for CRC 
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3. Materials 
3.1 Chemicals and reagents 
Application Chemical compound Supplier 
Cell culture 
FCS Life Technologies  
Penicillin-Streptomycin (10,000 U/mL) Life Technologies 
DMEM medium Life Technologies  
Mc Coy’s medium Life Technologies 
HBSS, no calcium, no magnesium, no phenol red Life Technologies 
etopside Sigma-Aldrich 
5-FU Sigma-Aldrich 
DMSO Carl Roth 
qPCR 
Fast SYBR® Green Master Mix Applied Biosystems 
Fast SYBR Green Master Mix Universal RT Exiqon A/S 
WB 
 
Protein A-Sepharose® from Staphylococcus aureus Sigma-Aldrich 
Rotiphorese gel 30 (37,5:1) Carl Roth 
APS Carl Roth 
TEMED Carl Roth 
Nonidet®P40 substitute Sigma-Aldrich 
sodium deoxycholate  Carl Roth 
SDS Carl Roth 
β-mercaptoethanol Sigma-Aldrich 
glycerol Carl Roth 
bromophenol blue Carl Roth 
complete mini protease inhibitor cocktail Roche 
PhosSTOP Phosphatase Inhibitor Cocktail  Roche 
Bradford reagent Bio-Rad 
PageRuler™ Prestained Protein Ladder Fermentas 
Immobilon-P PVDF,0.45μm Membrane Merck Millipore 
skim milk powder Sigma-Aldrich 
Methanol Carl Roth 
ECL/HRP substrate Merck Millipore 
IF 
PFA Merck KgaA 
FCS Life Technologies  
DAPI  Carl Roth 
Triton X 100 Carl Roth 
Tween 20 Sigma-Aldrich 
ProLong Gold antifade  Invitrogen  
Modified 
Boyden-cha
mber assay 
DAPI  Carl Roth 
BD Matrigel™ Basement Membrane Matrix BD Bioscience 
Triton X 100 Carl Roth 
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Application Chemical compound Supplier 
ChIP 
Protein G Sepharose®, Fast Flow Sigma-Aldrich 
BSA fatty acid free Sigma-Aldrich 
Salmon Sperm DNA Promega 
37% formaldehyde Merck Millipore 
Luciferase 
reporter 
assays 
 
ampicillin Sigma-Aldrich 
water (molecular biological grade) Life Technologies  
LB-Agar (Lennox) Carl Roth 
LB-Medium (Luria/Miller) Carl Roth 
Hi-Di™ Formamide Applied Biosystems 
sea plaque® agarose Lonza 
O’Gene Ruler 1kb DNA ladder Fermentas 
ethidium bromide Carl Roth 
HiPerFect Transfection Reagent Qiagen 
Opti-MEM® Reduced Serum Medium Life Technologies 
Generation 
of vectors 
ampicillin Sigma-Aldrich 
water (molecular biological grade) Life Technologies 
LB-Agar (Lennox) Carl Roth 
LB-Medium (Luria/Miller) Carl Roth 
Hi-Di™ Formamide Applied Biosystems 
sea plaque® agarose Lonza 
O’Gene Ruler 1kb DNA ladder Fermentas 
ethidium bromide Carl Roth 
Lipofectamine® 2000 Transfection Reagent Invitrogen 
Chloroquine Sigma-Aldrich 
Opti-MEM® Reduced Serum Medium Life Technologies 
puromycin dihydrochloride Sigma-Aldrich 
doxycycline hyclate Sigma-Aldrich 
IHC 
H2O2 Carl Roth 
Hematoxylin vector laboratories  
xylol Carl Roth 
Goat Serum Invitrogen 
Rabbit Serum Invitrogen 
Colony 
formation 
assay 
Crystal violet Carl Roth 
Acetic acid Carl Roth 
Methanol Carl Roth 
Wound 
healing  
Mitomycin C  Sigma-Aldrich 
Xenograft 
D-luciferin Caliper Life 
Sciences 
Tumoroid BD Matrigel™ Basement Membrane Matrix BD Bioscience 
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3.2 Buffers and solutions 
2x Laemmli buffer:  
125 mM TrisHCl (pH 6.8); 4% SDS; 20% glycerol; 0.05% bromophenol blue (in H2O); 
10% β-mercaptoethanol (added right before use) 
 
10x ‘Vogelstein‘ PCR buffer:  
166 mM NH4SO4; 670 mM Tris (pH 8.8); 67 mM MgCl2; 100 mM β-mercaptoethanol  
 
RIPA buffer (for protein lysates):  
1% NP40; 0.5% sodium deoxycholate; 0.1% SDS; 250 mM NaCl; 50 mM TrisHCl (pH 
8.0)  
 
SDS buffer:  
50 mM Tris (pH 8.1); 100 mM NaCl; 0.5% SDS; 5 mM EDTA  
 
10x Tris-glycine-SDS running buffer (5l, for SDS-PAGE):  
720 g Glycin; 150 g Tris base; 50 g SDS; pH 8.3-8.7; ad 5 l ddH2O 
 
Towbin buffer (for Western blotting):  
200 mM glycine; 20% methanol; 25 mM Tris base (pH 8.6) 
 
10x TBS-T (5l):  
500 ml 1M Tris (pH 8.0); 438.3 g NaCl; 50 ml Tween20; ad 5 l ddH2O 
 
10x PBS (1l):  
80g NaCl; 1g KCl; 14.42g Na2HPO4*2H2O; 2g KH2PO4; ad 1 l ddH2O 
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3.3 Kits 
Application Kit Supplier 
qPCR 
High Pure RNA Isolation Kit Roche 
High Pure miRNA Isolation Kit Roche 
miRCURY LNATM Universal RT microRNA PCR – 
Universal cDNA Synthesis Kit II 
Exiqon A/S 
Verso cDNA Kit 
Thermo Fisher 
Scientific 
WB BCA Protein Assay Kit  
Thermo Fisher 
Scientific 
IHC 
Dakocytomation Target Retrieval Solution citrate 
(10×) 
Agilent 
DAB 
vector 
laboratories 
Generation of 
vectors 
QIAamp DNA Micro Kit QIAGEN 
High Pure RNA Isolation Kit Roche 
Verso cDNA Kit 
Thermo Fisher 
Scientific 
QIAquick Gel Extraction Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
Pure Yield™ Plasmid Midiprep System Promega 
QIAprep Spin Miniprep Kit QIAGEN 
BigDye® Terminator v3.1 Cycle Sequencing Kit  Life Technologies 
DyeEx® 2.0 Spin Kit QIAGEN 
QuikChange  II XL Site-Directed Mutagenesis Kit 
Agilent 
Technologies 
DNA isolation DNeasy Blood & Tissue Kit  Qiagen 
Luciferase reporter 
assays 
Dual-Luciferase® Reporter Assay System Promega 
 
3.4 Enzymes 
Application Enzyme Supplier 
Cell culture Trypsin-EDTA (0.5%, 10x, phenol-red free) Invitrogen 
qPCR DNase I (RNase-free) Sigma-Aldrich 
Generation 
of vectors 
restriction endonucleases New England Biolabs 
Platinum® Taq DNA polymerase Invitrogen 
Pfu polymerase Thermo Fisher Scientific 
FIREPol® DNA Polymerase Solis BioDyne 
T4 DNA ligase Thermo Fisher Scientific 
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3.5 Antibodies 
3.5.1 Primary antibodies 
epitope species  catalog no. company use dilution source 
Vimentin human # 2707-1 Epitomics WB 1:500 rabbit 
E-cadherin  
human # 334000 Invitrogen WB; IF 1:1000; 
1:50 
mouse 
β-actin human # A2066 Sigma-Aldrich WB 1:1000 rabbit 
p53 human # sc-126 Santa Cruz WB 1:1000 mouse 
α-tubulin human  # T-9026 Sigma-Aldrich WB 1:1000 mouse 
SNAIL  human # 3879S Cell Signaling WB 1:500 rabbit 
STAT3 human # sc-482 Santa Cruz WB 1:1000 rabbit 
STAT3
pS727
 human  # 9134 Cell Signaling WB 1:1000 rabbit 
STAT3
pY705
 human  # 9131 Cell Signaling WB 1:1000 rabbit 
VSV human # V4888 Sigma-Aldrich WB; co-IP 1:1000 rabbit 
GLUT1 human # sc-377228 Santa Cruz IHC 1:100 mouse 
Laminin 
5γ2 
human # MAB19562 Merck Millipore IHC 1:100 mouse 
HIF1A human # NB100-105 Novus Biologicals WB; CHIP 1: 1000 mouse 
INH3 
Human # sc-376034 Santa Cruz WB; IHC; co-IP 1: 1000; 
1:100 
mouse 
HIF1A mouse # LS-B12555 LSBio WB; IHC 1: 500 rabbit 
INH3 mouse # SAB4502938 Sigma-Aldrich WB; IHC 1:500 rabbit 
Cleaved 
caspase-3 
mouse # 9661 Cell Signaling IHC 1:400 rabbit 
 
3.5.2 Secondary antibodies 
Secondary antibodies or conjugates 
name ordering no. company use dilution source 
anti-mouse HRP # W4021 Promega WB 1:10.000 goat 
anti-rabbit HRP # A0545 Sigma WB 1:10.000 goat 
Anti-Rabbit-Cy3 
# 715-165-150 Jackson 
Immuno-Research  
IF 1:100 donkey 
Alexa Flour 555-conjugated 
anti-mouse 
# A21422 Invitrogen IF 1:500 goat 
Phalloidin-conjugated 
Alexa-647 
# A22287 Invitrogen IF 1:40  -- 
Alexa Flour 555-conjugated 
anti-rabbit 
# A-11034 Invitrogen IF 1:1000 goat 
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3.6 Oligonucleotides 
3.6.1 Oligonucleotides used for qPCR 
gene  forward (5’-3’) reverse (5’-3’) 
human: 
β-actin  TGACATTAAGGAGAAGCTGTGCTAC GAGTTGAAGGTAGTTTCGTGGATG 
VIM  TACAGGAAGCTGCTGGAAGG  ACCAGAGGGAGTGAATCCAG  
CDH1  CCCGGGACAACGTTTATTAC  GCTGGCTCAAGTCAAAGTCC  
pri-miR-34a  CGTCACCTCTTAGGCTTGGA  CATTGGTGTCGTTGTGCT  
SLUG  GGGGAGAAGCCTTTTTCTTG  TCCTCATGTTTGTGCAGGAG  
STAT3 GGGAAGAATCACGCCTTCTAC  ATCTGCTGCTTCTCCGTCAC  
SNAIL GCACATCCGAAGCCACAC  GGAGAAGGTCCGAGCACAC  
FN CTTTGGTGCAGCACAACTTC TCCTCCTCGAGTCTGAACCA 
Inh3 CTGTGTCTGTCTGGCCCTAA GGGTGGGTATTGGGAGGAAA 
ZEB1  TCAAAAGGAAGTCAATGGACAA  GTGCAGGAGGGACCTCTTTA  
murine: 
β-actin  CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 
VIM  ATCGACAAGGTGCGCTTCC TTGCCCTGGCCCTTGA 
CDH1  GATTTGAGCCAGCTGCACAG GGGTGGGAGCCACATCATT 
pri-miR-34a  CTGTGCCCTCTTGCAAAAGG GGACATTCAGGTGAGGGTCTTG 
SLUG  ATCCTCACCTCGGGAGCAT GGTAGAGGAGAGTGGAGTGGAGC 
SNAIL CACACGCTGCCTTGTGTCT GGTCAGCAAAAGCACGGTT 
FN AGTGCTTCATGCCGCTAGAT GGGTGAAAGGACCACTCAAA 
Inh3 ACAACCGAGCCAGAGAATCA AAGGCCCGAGGCTTCTCATA 
ZEB1  GCATGTGACCTGTGTGACAA GATAGGGCTTTTCCCCAGAG 
ZEB2 ATTGCACATCAGACTTTGAGGAA ATAATGGCCGTGTCGCTTCG 
Twist CCCACCCCACTTTTTGACGA GGGATGCCTTTCCTGTCAGT 
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3.6.2 Oligonucleotides used for cloning and mutagenesis of Inh3 3’-UTRs 
gene forward (5’-3’) reverse (5’-3’) 
human: 
Inh3 3‘-UTR TCCCTCTCTCCTCCAGCATT  CCGGATCCCAGTAAGGGGTA 
Inh3 3‘-UTR 
site1 mutant  
CCAGTGTCTTCCTTTTGTTCTCA
GTCGGAAACTGCCTGTCCTGGG 
CCCAGGACAGGCAGTTTCCGACT
GAGAACAAAAGGAAGACACTGG 
Inh3 3‘-UTR 
site2 mutant 
CAACAGTCCCAGCTTTCAGTCG
GAGGGTCCCAGTCAGATTCC 
GGAATCTGACTGGGACCCTCCGA
CTGAAAGCTGGGACTGTTG 
murine: 
Inh3 3‘-UTR TCACCATTCATGTGTCTGCCT AAGTGGTGCCATGGGTTTTG 
Inh3 3‘-UTR 
site1 mutant  
CTATCCCTTTTGTTCTCAGTCGG
AAACTACCTGTCCTGGGATCC 
GGATCCCAGGACAGGTAGTTTCC
GACTGAGAACAAAAGGGATAG 
Inh3 3‘-UTR 
site2 mutant 
CAACGGTCCCAGCTTTCAGTCG
GAGGGCTCCAATCAGATGCC 
GGCATCTGATTGGAGCCCTCCGA
CTGAAAGCTGGGACCGTTG 
 
3.6.3 Oligonucleotides used for qCHIP 
gene  
forward (5’-3’) reverse (5’-3’) 
16q22  
CTACTCACTTATCCATCCAGGCT
AC 
ATTTCACACACTCAGACATCAC
AG 
miR-34a HRE1 ATAATGGTTGGGGCAGGAGG TAAAGGTTCCCAGAGACGCA 
miR-34a HRE2 TCGCATCTTGTTGAATCCGG AGGGCCTCTCGCCTGGA  
miR-34a HRE3 CGGTGAAGGGGATGAGGACCAG GCGGCATCTCCTCCACCTGAAA 
Inh3 HRE1 AACCTACTTGTCGGCCTTCC ATTCGTTCTCTCTGGGGTGA 
Inh3 HRE2 TTACGCGCCTCCATCTTCAA AAGTGGGAGCAGTTGGAAAC 
Inh3 HRE3 GCTTGGTGCACACAACTCC AACAAATTTGGCGGAAGGGG 
Inh3 HRE4 CCCCTTCCGCCAAATTTGTT AGGCGTCGCTGGATTAGTT 
Inh3 HRE5 CTCCCTGTCCTGAGCCTTAG GCCTAGCTCCTCCAACAACT 
VEGF CCTTTGGGTTTTGCCAGA CCAAGTTTGTGGAGCTGA 
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3.6.4 Oligonucleotides used for cloning and mutagenesis of human miR-34a 
promoter 
gene forward (5’-3’) reverse (5’-3’) 
miR-34a 
promoter 
CTGAGAGTGGGTATGGGAT
TGCC  
GCAGGACTCCCGCAAAATCTC
CAAATG 
miR-34a HRE2 
mutant 
CACACCCGCGTCCAGGAAA
GGGGTTTCTTCCCTCTTC 
GAAGAGGGAAGAAACCCCTTT
CCTGGACGCGGGTGTG 
 
3.6.5 Oligonucleotides used for cloning of human Inh3 
gene  forward (5’-3’) reverse (5’-3’) 
Inh3 CGGGATCCTCCCTGTCCTGAGCC
TTAGC 
ACGCGTCGACGTGCTGCATTGGCCCT
GGAG 
 
3.6.6 microRNA mimics and antagomiRs 
The following pre-microRNA mimics and antagomiRs were purchased from Ambion: 
pre-miR miRNA Precursor Negative Control # 1 (# AM17110); pre-miR-34a (# 
PM11030); pre-miR-34c (# PM11039); anti-miR Negative Control # 1 (# AM17010); 
has-miR-34a-5p anti-miR miRNA Inhibitor(# AM11030) 
 
3.6.7 siRNAs 
The following siRNAs were purchased from Ambion: 
Negative control (ID # 4611), STAT3 (ID # 6880), INH3 (ID # s13943), and HIF1A (ID 
# s6539). 
 
3.7 Search Algorithms 
application internet Supplier 
miR-34 binding 
site prediction 
miRwalk http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/ 
miR-34 binding 
site prediction 
targetscan http://www.targetscan.org/vert_71/ 
 
Materials 
28 
 
3.8 Vectors 
Name Insert Reference 
pRTR -- 
180
 
pRTR-p53-VSV  human TP53  
181
 
pCDNA3.1-p53-VSV human TP53  
pRTR-pri-miR-34a human miR-34a 
182
 
tTA-p53 human TP53 
183
 
pGL3-control-MCS -- 
71
 
pGL3-Inh3 wt human Inh3 3’UTR  
pGL3-Inh3 mut1 human Inh3 3’UTR  
pGL3-Inh3 mut2 human Inh3 3’UTR  
pGL3-Inh3 mut1 + 2 human Inh3 3’UTR  
pGL3-mInh3 wt mouse Inh3 3’UTR  
pGL3-mInh3 mut1 mouse Inh3 3’UTR  
pGL3-mInh3 mut2 mouse Inh3 3’UTR  
pGL3-mInh3 mut1 + 2 mouse Inh3 3’UTR  
pRL Renilla 
184
 
pBV -- 
185
 
pBV-miR-34a human miR-34a promoter  
HA-HIF1A human HIF1A with activating mutation 
186
 
 
3.9 Mice 
application Mice Supplier 
Xenograft NOD/SCID mice Jackson Laboratory 
IHC 
miR-34a
-/-
; miR-34bc
-/-
; Apc
Min/+
 and 
miR-34a
+/+
; miR-34bc
+/+
; Apc
Min/+
 mice 
Dr. Alexander Nikitin ;  
Dr. Marlon Schneider 
Tumoroid 
miR-34a
-/-
; miR-34bc
-/-
; Apc
Min/+
 and 
miR-34a
+/+
; miR-34bc
+/+
; Apc
Min/+
 mice 
Dr. Alexander Nikitin ;  
Dr. Marlon Schneider 
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3.10 Cell lines 
Species Cell lines Medium Supplier 
Human CRC cell 
lines 
SW480 DMEM Medium +  
10% FBS 
-- 
SW620 -- 
DLD-1 McCoy`s 5A Medium 
+ 10% FBS 
 
-- 
HT29 -- 
HCT15 -- 
HCT116 TP53
-/-
 Bert Vogelstein (Johns 
Hopkins University, 
Baltimore) 
HCT116 TP53
+/+
 
RKO TP53
-/-
 
RKO TP53
+/+
 
SW48 TP53
-/-
 
SW48 TP53
+/+
 
Murine CRC cell 
line 
CT26 
Gabriele Multhoff 
(Technical University, 
Munich) 
Human kidney cell 
line 
HEK293 
DMEM Medium +  
5% FBS 
-- 
 
3.11 Software 
application software Supplier 
Data analysis SPSS Statistics 23.0 IBM 
Data analysis and figure 
generation 
Prism5 program Graph Pad Software 
Inc. 
WB 
Varioskan Flash Multimode Reader Thermo Scientific 
KODAK MI SE software Carestream Health 
qPCR ND 1000 NanoDrop Spectrophotometer NanoDrop products 
Sequencing analysis 
DNA Sequencing Analysis Software v5 Applied Biosystems 
BioEdit BioEdit 
qPCR LightCycler 480  Roche 
IF ZEN 2009 Zeiss 
Wound healing assay Axiovision Zeiss 
Morphology  Axiovision Zeiss 
IHC Axiovision Zeiss 
Luciferase reporter 
assays 
SIMPLICITY software package DLR 
Modified Boyden-chamber Axiovision Zeiss 
Xenograft IVIS Illumina System Caliper Life Sciences 
Ectopic expression BD ACCURI C6 bdbiosciences 
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3.12 Laboratory equipment 
application Device Supplier 
qPCR 
ND 1000 NanoDrop Spectrophotometer NanoDrop 
LightCycler 480  Roche 
WB 
Mini-PROTEAN®-electrophoresis system Bio-Rad 
HTU SONI130 
G. Heinemann 
Ultraschall- und 
Labortechnik 
Varioskan Flash Multimode Reader Thermo Scientific 
PerfectBlue™ SEDEC ‘Semi-Dry’ blotting 
system 
Peqlab Biotechnologie 
Mini Trans-Blot® Electrophoretic Transfer 
Cell 
Bio-Rad 
Powerpac 300 Power Supply Bio-Rad 
biophotometer plus eppendorf 
EPS 600 power supply Pharmacia Biotech 
440CF imaging system Eastman Kodak 
Modified 
Boyden-chamber assay 
Boyden chamber transwell membranes 
(pore size 8.0 µm) 
Corning 
Axiovert 25 microscope Carl Zeiss 
Cell culture 
Herasafe KS class II safety cabinet 
Thermo Fisher 
Scientific 
Neubauer counting chamber Carl Roth 
Sequencing 
ABI 3130 genetic analyzer capillary 
sequencer 
Applied Biosystems 
IF Axiovert 25 microscope Carl Zeiss 
IHC Axiovert 25 microscope Carl Zeiss 
Ectopic expression 
Fisherbrand FT-20E/365 transilluminator Fisher Scientific 
GeneAmp® PCR System 9700 Applied Biosystems 
MultiImage Light Cabinet Alpha Innotech 
BD AccuriTM C6 Flow Cytometer 
Instrument 
BD Accuri 
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application Device Supplier 
Wound healing assay 
Culture-Insert 2 Well ibidi 
Axiovert 25 microscope Carl Zeiss 
Luciferase reporter 
assays 
Orion II luminometer Berthold Technologies 
Xenograft 
IVIS Illumina System Caliper Life Sciences 
Colony formation assay Varioskan Flash Multimode Reader Thermo Scientific 
Cell proliferation real-time cell analyzer (RTCA) Roche 
Common used 
Forma scientific CO2 water jacketed 
incubator 
Thermo Fisher 
Scientific 
Falcons, dishes and cell culture materials 
Schubert & Weiss 
OMNILAB 
5417C table-top centrifuge Eppendorf 
waterbath Memmert 
Biofuge pico table top centrifuge 
Thermo Fisher 
Scientific 
Megafuge 1.0R 
Thermo Fisher 
Scientific 
Biofuge fresco 
Thermo Fisher 
Scientific 
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4. Methods 
4.1 Bacterial culture 
4.1.1 Propagation and seeding 
  For replication of plasmids harboring an ampicillin or kanamycin resistance, 
bacterial E.coli XL1-blue strain was used. The bacterial cells were cultured either in 
liquid LB-medium by agitation (225 rpm) or on LB agar plates at 37°C overnight. 
LB-medium or LB agar plates were supplemented with 100 μg/ml ampicillin or 50 
μg/ml kanamycin. 
 
4.1.2 Transformation 
  In order to transform the plasmids harboring an ampicillin or kanamycin resistance, 
competent bacterial E.coli XL1-blue strain was used. In general, approximately 100 
ng of plasmid DNA was added to 200 µl aliquots of competent bacterial E.coli 
XL1-blue and incubated on ice for thirty minutes. The competent cells were subjected 
to a heat -shock at 42°C for ninety seconds and then placed on ice for additional two 
minutes. Subsequently, 1 ml of antibiotic-free LB-medium was added and 
pre-incubated at 37°C for one hour. Next, the cells were plated on LB-agar plates 
containing ampicillin or kanamycin and cultured at 37°C overnight. For further 
propagation of the plasmid a transformed single cell clone was used to inoculate the 
respective amount of LB-medium containing the corresponded antibiotics, and then 
was incubated at 37°C overnight and subjected to the procedure of plasmid DNA 
purification. 
 
4.1.3 Purification of plasmid DNA from E.coli 
  In order to prepare small amounts of plasmid DNA, bacterial, transformed with 
plasmids, were incubated in a volume of 5 ml of LB-medium supplemented with 
ampicillin or kanamycin. The plasmid DNA was isolated according to the 
manufacturer’s instructions of the QIAprep Spin Miniprep Kit (Qiagen). The method 
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was preferentially used due to the better yield and quality of DNA for high transfection 
efficiency.  
  In order to prepare large amounts of plasmid DNA, bacterial cells were incubated in 
a volume of 150 ml of LB-medium containing ampicillin or kanamycin. Pure Yield™ 
Plasmid Midiprep System (Promega) was used according to the protocol of the 
manufacturer for DNA purification. 
 
4.1.4 Sequence inserts DNA in plasmid  
  In order to verify DNA sequences introduced into plasmid, DNA sequencing was 
conducted according to the manufacturer’s instructions of BigDye Terminator v1.1 
Cycle Sequencing Kit (Life Technologies). Briefly, master mix was prepared 
containing Big Dye Terminator V1.1, 5×Sequencing buffer, primer (10 μM), plasmid (1 
μg/ml). And then the PCR program was conducted by 15 cycles of each ten seconds 
at 96°C and ninety seconds at 60°C. Subsequently, the DyeEx 2.0 Spin Kit (Qiagen) 
was used according to the manufacturer’s protocol in a 5417C centrifuge (Eppendorf). 
After that, purified DNA was mixed with Hi-Di Formamide (Applied Biosystems), and 
loaded into to ABI3130 genetic analyzer capillary sequencer (Applied Biosystems) for 
sequencing. Data was analyzed by applying the 3130 Data Collection Software v3.0 
and the sequencing analysis software 5.2 (Applied Biosystems).  
 
4.2 Polymerase Chain Reaction (PCR) methods 
4.2.1 Colony PCR 
  To verify the identity and orientation of DNA inserts colony PCR was conducted. 
For this, 20 µl PCR master mix containing vector and/or insert specific primers, 
dNTPs, 10x Vogelstein PCR buffer and FIREPol® DNA polymerase was prepared. 
Single colonies were picked from the LB-agar plate and transferred into correspond 
PCR tube. The PCR cycling conditions were the following: 95°C for five minutes, 
followed by 25 cycles of 95°C for twenty seconds, 55°C for thirty seconds and 72°C 
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for X minute/s (1 minute per 1 kb length of the expected PCR product), and then 
another 72°C for seven minutes. PCR fragment length was analyzed by 
supplementing the sample with loading dye and loading it into agarose gel 
(percentage of the gel adjusted to the fragment length) for electrophoresis.  
 
4.2.2 Cloning of the human miR-34a promoter 
  The promoter region 2 kbp upstream of the transcriptional start site of human 
miR-34a gene was PCR-amplified from genomic DNA of human diploid fibroblasts 
(HDFs). The PCR product was cloned into the shuttle vector pGEM-T-Easy 
(Promega), then transferred into the pBV-MCS vector and verified by sequencing. 
Mutagenesis of the promoter sequence was achieved using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer’s instructions 
and verified by sequencing. The sequences of oligonucleotides used as cloning and 
mutagenesis of human miR-34a promoter primers are listed in Table 3.6.4. 
 
4.2.3 Cloning of 3 -́UTR sequences 
  The full-length 3’-UTRs of the human and mouse Inh3 mRNAs were PCR-amplified 
from cDNA of human diploid fibroblasts (HDFs) and mouse embryonic fibroblasts 
(MEFs), respectively. The PCR product was cloned into the shuttle vector 
pGEM-T-Easy (Promega), and then transferred into the pGL3-control-MCS vector 71 
and verified by sequencing. Mutagenesis of the miR-34a seed-matching sequences in 
human and mouse was achieved using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene) according to manufacturer’s instructions and verified by 
sequencing. The sequences of oligonucleotides used as cloning and mutagenesis of 
human and mouse 3‘-UTR primers are listed in Table 3.6.2. 
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4.2.4 Episomal vectors for ectopic expression of proteins 
  The generation of the pRTR vector, which is an improved version of the pRTS 
vector is described in 180. To generate the episomal pRTR-Inh3-VSV vector, the Inh3 
ORF was isolated from cDNA of HDFs, and ligated into the modified pUC19-SfiI 
shuttle vector pUC19-SfiI-CVSV, in which a VSV-tag was inserted via XhoI and XbaI 
restriction sites (Figure 4.1), via BamHI and SalI restriction sites, released with SfiI, 
and the resulting fragment was ligated into pRTR. The insert orientation and the 
ORFs were verified by sequencing. The sequences of oligonucleotides used as 
cloning human Inh3 primers are listed in Table 3.6.5. More detailed information on the 
generation of p53 or the pri-miR-34a pRTR vectors is provided in 48, 182. Other 
expression plasmids are listed in Table 3.8.  
 
 
Figure 4.1 Schematic map of pUC19(sfiI)-CVSV. 
 
4.3 Cell culture of human cells 
4.3.1 Propagation of human cell lines 
  The human colorectal cancer cell lines SW480 and SW620, as well as human 
diploid fibroblasts (HDFs) were maintained in high glucose Dulbecco`s modified 
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Eagles medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS). 
Human breast cancer cell line HEK293T was cultured in high glucose Dulbecco`s 
modified Eagles medium (DMEM, Invitrogen) containing 5% FBS. The human 
colorectal cancer cell lines HCT-15, HT29, DLD-1, HCT116, RKO, SW48 and CT26 
and their derivatives were cultured in McCoys medium (Invitrogen) containing 10% 
FBS. TP53-/- and TP53+/+ HCT116, RKO and SW48 lines were kindly provided by Bert 
Vogelstein (Johns Hopkins University, Baltimore) and CT26 cells by Gabriele Multhoff 
(Technical University, Munich). All cells were cultivated in presence of 100 units/ml 
penicillin and 0.1 mg/ml streptomycin at 20% O2, 5% CO2 and 37°C. Cells used are 
listed in Table 3.10. Hypoxia was achieved using a CD210 incubator (Binder). In 
order to avoid any confluency of the cells, they were passaged every two to four days 
and seeded into fresh culturing flasks. Doxycycline (DOX; Sigma) was dissolved in 
water (100 µg/ml stock solution) and used at a final concentration of 100 ng/ml. CoCl2 
(Cobalt (II) chloride) was dissolved in water and used at a final concentration of 40 
ng/ml. Etoposide (Sigma) was used at a concentration of 20 µM and 5-FU (Sigma) at 
25 µg/ml.  SiRNAs (silencer siRNA (Ambion): negative control (ID # 4611), STAT3 
(ID # 6880), INH3 (ID # s13943), and HIF1A (ID # s6539)) were transfected at a final 
concentration of 10 nM using HiPerfect transfection reagent (Qiagen). 
 
4.3.2 Transfection of oligonucleotides and vector constructs 
  Transfections of oligonucleotides and vector constructs were carried out using 
freshly trypsinized and seeded cells in the medium and cell culturing format of choice, 
preferentially into a six- or twelve-well format.  
  In order to transfect oligonucleotides HiPerFect (Qiagen) was used. For six-well 
format, the transfection reagent mix contained 100 µl Opti-MEM (Invitrogen), 10 µl 
HiPerFect (Qiagen) and 10 µl of the respective oligonucleotide (10 µM) (Ambion – 
Applied Biosystems, final concentration (100 nM)).  
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  In order to transfect plasmid DNA, the transfection mix consisted of 150 µl 
Opti-MEM, 5 µl Lipofectamine® 2000 Transfection Reagent (Invitrogen) and 
incubated at room temperature for five minutes. In the meanwhile, prepare the mix 
consisted of 150 µl Opti-MEM, 4 µg DNA. Mix these two mixtures. Before adding the 
mix drop-wise to the cells, it was incubated at room temperature for fifteen to twenty 
minutes. After incubation, the respective assays were carried out. Selection of 
plasmid containing cells was started twenty four hours after transfection using 
appropriate antibiotics.  
 
4.3.3 Generation of cell pools stably expressing conditional alleles 
  Stable transfection cells were generated as described previously 48. Briefly, cells 
were transfected with pRTR plasmids using FuGene reagent (Roche). After 24 hours, 
cells were transferred into media containing 4 µg/ml puromycin for one week. 
Homogeneity of the derived cell pools was tested by addition of 100 ng/ml DOX for 48 
hours and evaluation of GFP expression by fluorescence microscopy.  
 
4.3.4 Cryo-Preservation of mammalian cells 
  Sub-confluent cells in the exponential growth phase were trypsinized, resuspended 
with medium and pelleted by centrifugation at 1200 rpm for five minutes. 
Resuspension of cells was done in 50% FCS, 40% growth medium and 10% (v/v) 
DMSO (Roth). Aliquots in cryo-vials were cooled down in a freezing device at -80°C 
and transferred into liquid nitrogen for long term storage.  
  For cell recovery, cryo-preserved cells were rapidly thawed in water bath at 37°C, 
resuspended in 10ml pre-warmed growth medium and pelleted by centrifugation at 
1200 rpm for five minutes. After that, the cells were resuspended in respective growth 
medium and transferred into T25 cell culture flask for further cultivation. 
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4.3.5 Analysis of the transfection efficiency by flow cytometry 
  In order to detect the transfection efficiency of the pRTR vectors harboring an eGFP 
gene into mammalian cells, the percentage of eGFP-positive cells was determined 
after seventy two hours with or without addition of DOX (100 ng/ml). A BD AccuriTM 
C6 Flow Cytometer instrument (Accuri) and the corresponding Cflow® software were 
used to read out the proportion of fluorescent cells. 
 
4.4 Isolation of genomic DNA from human diploid fibroblasts (HDFs) 
  Genomic DNA from HDFs was generated by seeding the cells on a 10 cm2 dish at a 
confluence of 90% at the maximum. The DNA was isolated according to 
manufacturer’s instructions using the Blood & Tissue Kit (Qiagen). The DNA 
concentration was measured using a Nanodrop spectrophotometer. 
 
4.5 RNA analysis 
4.5.1 Isolation of RNA and reverse transcription 
  Total RNA was isolated with the High Pure RNA Isolation Kit (Roche) according to 
the manufacturer’s instructions. A Nanodrop spectrophotometer was used to 
determine the amount and quality of the RNA. For mRNA and primary miRNA 
analysis 1 µg of total RNA per sample was used to generate cDNA using the Verso 
cDNA synthesis kit (Thermo scientific).  
  For the detection of mature miRNAs, a High Pure miRNA Isolation Kit (Roche) was 
used to isolate small RNAs according to the manufacturer’s instructions. After 
determining the amount and quality of the RNA by Nanodrop spectrophotometer, 
cDNA was synthesized from 500 ng of RNA per sample by applying the Exiqon 
Universal cDNA Synthesis Kit from the miRCURY LNA Universal RT microRNA PCR 
Kit (Exiqon, 203300) according to the manufacturer ś instructions. Primers specific for 
miR-34a (Exiqon: # 204486) and respective control primer SNORD48 (Exiqon: # 
203903) were used for miRNA LNA PCR. 
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4.5.2 Quantitative Real-Time PCR (qPCR) and Exiqon qPCR 
  Quantitative real-time PCR (qPCR) was performed with the Fast SYBR Green 
Master Mix (Applied Biosystems) on a LightCycler 480 (Roche). For mature miRNA 
analyses, qPCR was performed using the Exiqon Universal cDNA Synthesis Kit, 
SYBR Green Master Mix Universal RT (Exiqon, # 203450), and commercially 
available primers (Exiqon). Expression of mRNA and primary miRNA was normalized 
to β-actin, mature miRNA expression were normalized to SNORD48. The qPCR 
results were calculated using the ΔΔCt method as described before 187. Results are 
represented as fold induction of the treated/transfected condition compared with the 
control condition Experiments were performed in triplicates. Oligonucleotides used for 
qPCR are provided in Table 3.6.1. 
 
4.6 Protein analysis 
4.6.1 Protein Isolation, SDS-PAGE and Western blot 
  Protein isolation, SDS-PAGE and Western blot were performed as described 
previously 79. Briefly, cells were washed with ice-cold PBS and harvested on ice using 
a plastic cell scraper and ice-cold RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 250 mM 
NaCl, 1% NP40, 0.5% (w/v) sodium deoxycholate, 0.1% sodium dodecylsulfate, 
complete mini protease inhibitor tablets (Roche) and Phosphatase Inhibitor tablets 
(Roche)). Lysates were sonicated using a HTU SONI130 (G. Heinemann Ultraschall- 
und Labortechnik) for three consecutive five-second pulses with 75% intensity. In 
order to separate the protein containing supernatant from any cell debris, the 
sonicated Lysates were centrifuged at 16.060 g for fifteen minutes at 4°C. After 
centrifugation, the supernatant containing protein lysate was transferred into a new 
tube. Protein concentration was measured with BCA Protein Assay Kit (Thermo 
Fisher Scientific) in Varioskan Flash Multimode Reader using the SkanIt RE for 
Varioskan 2.4.3 software (Thermo Scientific).  
Methods 
40 
 
  7.5 to 15% polyacrylamide protein gels were prepared depending on the size of 
analyzed proteins and overlaid with 4% stacking gel.  
  Subsequently, 30 to 60 µg of whole cell lysate per lane was supplemented with 
4×Laemmlie buffer, denatured at 95°C for five minutes, and loaded on 7.5 to 15% 
SDS-acrylamide gels according to protein sizes. A pre-stained protein ladder 
(Fermentas) served as size control. Separation of the proteins by electrophoresis was 
performed at 60-130 V in a Mini-PROTEAN®-electrophoresis system (Bio-Rad) with 
Tris-glycine-SDS running buffer. The separated proteins were transferred onto 
Immobilon PVDF membranes (Millipore) with Towbin buffer using the PerfectBlue™ 
SEDEC blotting system (Peqlab) and a EPS 600 power supply (Pharmacia Biotech) 
constantly at a 125 mA per gel and a maximum voltage of 10 V. 
  To block unspecific protein binding, membranes were incubated for one hour in 5% 
skim milk/TBS-Tween20 (TBS-T). Then membranes were incubated with the primary 
antibodies (diluted in TBS-T) at 4°C overnight. The membranes were washed three 
times in TBS-T for ten-minute each. Then membranes were incubated with 
horseradish-peroxidase (HRP)-conjugated secondary antibodies for one hour at room 
temperature. Three times washing was conducted as describe above. Enhanced 
Chemiluminescence (ECL, Millipore) signals were recorded with 440CF imaging 
system (Eastman Kodak Co.). Antibodies used here are listed in Table 3.5. 
 
4.6.2 Quantification of Western blot Signals 
  Intensities of protein band signals were quantified by densitometric analysis using 
KODAK MI SE software (Carestream Health). The resulting values were used for 
calculating the ratio of respective protein to loading control. The quotient of the 
respective experimental control was set equal to one. 
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4.6.3 Co-immunoprecipitation (Co-IP) analysis 
  For co-immunoprecipitation analysis, cell lysates were prepared in RIPA lysis buffer 
with Complete Mini Protease and Phosphatase Inhibitors (Roche) added, sonicated 
and centrifuged at 16.060 g for 15 min at 4°C. The immunoprecipitations were 
performed overnight at 4 °C with antibodies to VSV (V4888, Sigma-Aldrich) or INH3 
(sc-376034, Santa Cruz) or corresponding IgG (as a control). Subsequently the 
immunoprecipitates were incubated at 4°C for 2 hours with Protein A-Sepharose 
beads (P9424, Sigma-Aldrich) for VSV antibody/Protein G-Sepharose beads (P3296, 
Sigma-Aldrich) for Inh3 antibody. Immunoprecipitates were collected by centrifugation 
and followed by 3 times washing with RIPA lysis buffer. Samples were resuspended 
in 4X sample buffer and subjected to Western blot analysis. Antibodies used here are 
listed in Table 3.5. 
 
4.7 Chromatin immunoprecipitation (ChIP) assay 
  DLD-1 cells and their derivatives were cultured as described above. Cross-linking 
and harvesting of cells was performed as previously described 188. Briefly, 
cross-linking was conducted with formaldehyde (Merck) at 1% final concentration and 
terminated after 5 minutes by addition of glycine at a final concentration of 0.125 M. 
Cells were harvested in SDS buffer (50 mM Tris pH 8.1, 0.5% SDS, 100 mM NaCl, 5 
mM EDTA), pelleted and resuspended in IP buffer (2 parts of SDS buffer and 1 part 
Triton dilution buffer (100 mM Tris-HCl pH 8.6, 100 mM NaCl, 5 mM EDTA, pH 8.0, 
0.2%  NaN3, 5.0% Triton X-100)). Chromatin was sheered by 8 sonication cycles 
(HTU SONI 130, G. Heinemann) to generate DNA fragments with an average size of 
700 bp for qChIP. Preclearing and incubation with monoclonal HIF1A antibody 
(H1alpha67) (NB100-105, Novus Biologicals) or mouse IgG antibody control (M-7023, 
Sigma) for 16 hours was performed as previously described 189. Washing and reversal 
of crosslinking was performed as described 190. ChIP-DNA was analyzed by qPCR 
and the enrichment was expressed as fold enrichment compared to IgG. Binding to a 
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region on chromosome 16q22 served as negative control in all ChIP assays 
performed. Antibodies used here are listed in Table 3.5. The sequences of 
oligonucleotides used as qChIP primers are listed in Supplemental Table 3.6.3. 
 
4.8 Indirect immunofluorescence and confocal laser-scanning microscopy 
  Cells cultivated on glass cover-slides were fixed in 4% paraformaldehyde/PBS for 
10 minutes, permeabelized in 0.2% Triton X 100 for 20 minutes and blocked in 100% 
FBS for 30 minutes. F-Actin was detected with Phalloidin conjugated with Alexa Flour 
647 (Invitrogen). Chromatin was stained by DAPI (Roth). Slides were covered with 
ProLong Gold Antifade (Invitrogen). Antibodies used here are listed in Table 3.5. 
CLSM (confocal laser scanning microscopy) images were captured with a LSM700 
microscope using a Plan Apochromat 20x/0.8 M27 objective and ZEN 2009 software 
(Zeiss) with the following settings: image size: 2048x2048 and 16 bit; pixel/dwell of 
25.2 µs; pixel size 0.31 µm; laser power 2% and master gain 600-1000. After image 
capturing the original CLSM files were converted into TIFF files. 
 
4.9 Modified Boyden-chamber assay for analysis of migration and invasion 
  Migration and invasion analyses were conducted as described previously 48. In 
short, cells were serum-starved by cultivation in 0.1% serum for 24 hours. To analyze 
migration, 5x104 cells were seeded in the upper chamber (8.0 µm pore size 
membrane; Corning) in serum-free medium. To analyze invasion, chamber 
membranes were first coated with Matrigel (BD Bioscience) at a dilution of 3.3 ng/ml 
in medium without serum. Then 8x104 cells were seeded on the Matrigel in the upper 
chamber in serum free medium. 10% FBS was placed as a chemo-attractant in the 
lower chamber. After cells were cultured for 48 hours, non-motile cells at the top of the 
filter were removed and the cells in the bottom chamber were fixed with methanol, 
stained with DAPI and counted using immunofluorescence microscopy. Relative 
invasion/migration was normalized to the corresponding control.  
Methods 
43 
 
4.10 Wound-healing assay 
  The wound healing assay was performed as described previously 31. In brief, 
Mitomycin C [10 ng/ml] was added two hours before generating a scratch using a 
Culture-Insert (IBIDI, 80241). After washing twice with HBSS to remove Mitomycin C 
and detached cells, medium was added. Cells were allowed to close the wound for 
the indicated periods. Images were captured on an Axiovert Observer Z.1 microscope 
connected to an AxioCam MRm camera using the Axiovision software (Zeiss). 
 
4.11 Luciferase reporter assay 
  H1299 cells were seeded in 12-well format dishes at 3×104 cells/well for 24 hours, 
transfected 100 ng of the respective firefly luciferase reporter plasmid, 20 ng of 
Renilla reporter plasmid as a normalization control and 25 nM of pre-miR-34a or 
pre-miR-34c (Ambion, PM11030, PM11039) or a negative control oligonucleotide 
(Ambion, neg. control #1) with HiPerFect Transfection Reagent (Qiagen). The 
analysis was performed with Dual Luciferase Reporter assay kit (Promega) according 
to manufacturer’s instructions. Luminescence intensities were measured by an Orion 
II luminometer (Berthold) in 96-well format and analyzed with the SIMPLICITY 
software package (DLR). 
 
4.12 Site directed mutagenesis 
  Putative seed matching sequences were mutated from CACTGCCA to 
CAGTCGGA in order to abolish the binding reaction. This was achieved with the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) using the 
respective mutagenic primers and performing the mutagenic reaction according to the 
manufacturer’s instructions. Plasmid sequences were verified by sequencing. 
Oligonucleotides used for cloning and mutagenesis are provided in Table 3.6.2. 
  The HRE2 site was mutated from ACGTG to AAAGG with the the QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies) using the respective mutagenic 
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primers and performing the mutagenic reaction according to the manufacturer’s 
instructions. Plasmid sequences were verified by sequencing. Oligonucleotides used 
for cloning and mutagenesis are provided in Table 3.6.4. 
 
4.13 RNA interference 
  For RNA interference, siRNAs (Ambion silencer siRNA negative control #1: 
ID#4611; STAT3-specific siRNAs: ID#6880; Inh3-specific siRNAs: ID#s13943; 
HIF1A-specific siRNAs: ID#s6539) were transfected at a final concentration of 10 nM 
for the indicated time-points using HiPerfect transfection reagent (Qiagen). 
 
4.14 Colony formation assay 
  For low-density, colony formation assays, 200-500 cells were seeded into a 6-well 
plate and cultivated for one day at 20% O2 and subsequently exposed to 0.5% O2 for 
two days, and subsequently treated with or without 5-FU for three days. Subsequently, 
cells were fixed and stained with crystal violet. Colonies were photographed and the 
staining was extracted by 33% Acetic acid and subsequently measured with a 
Varioskan Flash Multimode Reader using SkanIt RE for Varioskan 2.4.3 software 
(Thermo Scientific). The measured values of were normalized to the corresponding 
controls. 
 
4.15 Analysis of TCGA-COAD data  
  The expression profiles of 425 colon adenocarcinomas were obtained from the 
TCGA data portal 106 (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). Spearman 
correlation coefficient analysis was performed with the Prism5 program (Graph Pad 
Software Inc.). 
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4.16 Animal experiments 
4.16.1 Animal experiments 
  NOD/SCID mice were purchased from the Jackson Laboratory. The generation of 
miR-34a-/- mice with a C57BL6/SV129 back-ground has been described previously 79. 
miR-34b/c-/- mice were kindly provided by Dr. Alexander Nikitin (Cornell University) 191. 
miR-34a-/-; b/c-/- compound mice were generated by crossing miR-34a-/- and 
miR-34b/c-/-. ApcMin/+ mice were kindly provided by Dr. Marlon Schneider. miR-34a-/-; 
b/c-/- and miR-34a+/+; miR-34bc+/+ mice were crossed with ApcMin/+ mice to obtain 
miR-34a/b/c-/-; ApcMin/+, and miR-34a/b/c+/+ ApcMin/+ mice. Mice were housed in 
individually ventilated cages (IVC) cages using “Lingocel Select” bedding. All 
experiments involving mice were conducted with approval by the local Animal 
Experimentation Committee (Regierung of Oberbayern). All experiments were 
performed in accordance with the ARRIVE guidelines and regulations.  
 
4.16.2 Metastasis formation in NOD/SCID mice 
  DLD-1 cells stably expressing Luc2 were generated as described previously 30. 
4x106/0.2 ml HBSS DLD-1-luc2 cells were injected into the lateral tail vein of 
NOD/SCID mice using 25-gauge needles. Cells transfected with Inh3 and control 
siRNAs were injected into sibling littermates. Anesthetized mice were injected 
intraperitoneal with D-luciferin (150 mg/kg) and imaged half hour after injection using 
the IVIS Illumina System (Caliper Life Sciences). In weekly intervals anesthetized 
mice were injected intraperitoneal with D-luciferin (150 mg/kg) and imaged ten 
minutes after injection using the IVIS Illumina System (Caliper Life Sciences). The 
acquisition time was two minutes. Seven weeks after tail vein injection, mice were 
sacrificed and examined for lung metastases using H&E (hematoxylin and eosin) 
staining, lungs were fixed with 4% paraformaldehyde and 5 µm paraffin sections were 
stained with H&E. The number of metastases was determined microscopically. All 
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studies involving mice were conducted with approval by the local Animal 
Experimentation Committee (Regierung of Oberbayern). 
 
4.16.3 Immunohistochemical analysis of murine adenomas 
  The samples were collected from 18 weeks old mice. MiR-34a-/-; miR-34bc-/-; 
ApcMin/+ and miR-34a+/+; miR-34bc+/+; ApcMin/+ samples were fixed in formalin, and 
paraffin embedded. 3 μm thick sections were de-paraffinized in xylene and rehydrated 
in serial dilution of ethanol and water prior to antigen retrieval in Target Retrieval 
Solution (pH6.0, Dako Cytomation) in a microwave oven and TBST washing. After 
neutralization of endogenous peroxidase with 3% H2O2 for ten minutes, the sections 
were incubated with 20% goat serum in TBST for 1 hour. Afterwards, primary 
antibodies were applied at 4°C overnight (HIF1A (LS-B12555, LSBio LifeSpan 
BioSciences), INH3 (SAB4502938, Sigma-Aldrich)). Anti-rabbit conjugated to HPR 
were applied at room temperature for 1 hour. DAB (3, 3'-diaminobenzidine, Dako) was 
used as a substrate-chromogen. After counterstaining with hematoxylin, the sections 
were analyzed using Zeiss LSM 700 confocal microscopy. Antibodies used here are 
listed in Table 3.5. 
 
4.16.4 Western blot analysis of murine adenomas 
  The samples were collected from 18 weeks old mice. For protein lysates from 
MiR-34a-/-; miR-34bc-/-; ApcMin/+ and miR-34a+/+; miR-34bc+/+; ApcMin/+ samples were 
lysed in RIPA buffer. Lysates were sonicated using a HTU SONI130 (G. Heinemann 
Ultraschall- und Labortechnik) and centrifuged at 16.060 g for fifteen minutes at 4°C. 
Protein concentration was measured with BCA Protein Assay Kit (Thermo Fisher 
Scientific) according to manufacturer’s instructions. The protein concentration was 
measured with a Varioskan Flash Multimode Reader using the SkanIt RE for 
Varioskan 2.4.3 software (Thermo Scientific). Subsequently, 30 to 60 µg of whole cell 
lysate per lane were loaded. The separation of the proteins by electrophoresis was 
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performed and were transferred onto Immobilon PVDF membranes (Millipore) using 
standard protocols (Bio-Rad laboratories). Enhanced Chemiluminescence (ECL, 
Millipore) signals were recorded with 440CF imaging system (Eastman Kodak Co.). 
Antibodies used here are listed in Table 3.5. 
 
4.16.5 qPCR analysis of murine adenomas 
  The samples were collected from 18 weeks old mice. Total RNA was isolated from 
MiR-34a-/-; miR-34bc-/-; ApcMin/+ and miR-34a+/+; miR-34bc+/+; ApcMin/+ samples using 
the RNeasy Plus Mini Kit (Qiagen). Nanodrop spectrophotometer was used to 
determine the amount and quality of the RNA. cDNA was generated using anchored 
oligo(dT) primers (Verso cDNA synthesis Kit (Thermo scientific)) following the 
manufacturer’s instructions. qPCR was performed by using Fast SYBR Green Master 
Mix (Applied Biosystems) and a LightCycler 480 II (Roche Diagnostics). The 
expression of mRNA and primary miRNA was normalized by detection of β-actin as 
previously described in 192. The qPCR results are indicated the fold of change, which 
was analysed by the comparative Ct (ΔΔCt) method with the control set to 1 as 
described before 187. Oligonucleotides used for qPCR are provided in Table 3.6.1.  
 
4.17 Tumoroid analysis 
4.17.1 Tumoroid culture 
  Intestinal adenoma cells from 18 weeks old miR-34a-/-; miR-34bc-/-; ApcMin/+ and 
miR-34a+/+; miR-34bc+/+; ApcMin/+ mice were isolated and counted using a 
hemocytometer. Single cells were embedded in Matrigel and seeded in 24-well plates 
(15,000 single cells per 50 μl Matrigel per well). The tumor organoid culture medium 
was formulated as described before 193. 
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4.17.2 Immunofluorescence staining of tumoroids 
  Tumoroids were fixed with 4% paraformaldehyde (PFA) for twenty minutes at room 
temperature, followed by permeabilization in 0.1% Triton X-100. Immunofluorescence 
was performed using antidodies specific for cleaved caspase-3 (9661, Cell Signaling 
Technology). The secondary antibody was Alexa Fluor 488 conjugated antibodies. 
DNA was stained with DAPI. The images of tumoroids were taken with a Zeiss LSM 
700 confocal microscope. Antibodies used here are listed in Table 3.5. 
 
4.18 Analysis of human CRC samples 
  INH3 expression was evaluated using formalin-fixed, paraffin-embedded (FFPE) 
colon cancer samples of 84 patients who underwent surgical tumor resection at the 
Ludwig-Maximilians University of Munich (LMU) between 1994 and 2005. Follow-up 
data were recorded by the tumor registry Munich. All tumors were located on the right 
side of the colon. Half of the patients had colon cancers with synchronous liver 
metastases diagnosed by clinical imaging or liver biopsy. Controls consisted of colon 
cancer patients without distant metastases at the time of diagnosis and with a 
disease-free survival of at least 5 years after primary surgical resection. The samples 
of cases and controls were matched by tumor grade (according to WHO 2000), 
T-classification (according to TNM Classification of Malignant Tumors 2009), and 
tumor localization, resulting in 42 matched pairs. Tissue microarrays (TMAs) were 
generated with 6 representative 1 mm cores of each case. 5 µm TMA sections were 
prepared, deparaffinized, and stained with INH3 antibody (sc-376034, Santa Cruz) or 
Laminin 5γ2 antibody (MAB19562, Merck Millipore) or GLUT1 antibody (sc-377228, 
Santa Cruz) on a Ventana Benchmark XT Autostainer with UltraView Universal DAB 
and alkaline phosphatase detection kits (Ventana Medical Systems). Frequencies 
were analyzed using the Chi-square test. Statistical procedures were performed using 
SPSS Statistics 23.0 (IBM). Samples and patient data were anonymized and the need 
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for consent was waived by the institutional ethics committee of the Medical Faculty of 
the LMU. Antibodies used here are listed in Table 3.5. 
 
4.19 Statistical analysis 
  Calculations of significant differences between two groups of samples were 
analyzed by a Student’s t-test (unpaired, two tailed) using Prism5 (Graph Pad 
Software Inc.). P-values ≤ 0.05 were considered as significant.  
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5. Results 
5.1 Hypoxia induces EMT via activation of HIF1A in CRC cells  
  In order to study the molecular regulation of hypoxia-induced EMT in CRC, the 
CRC cell lines DLD-1, HT29, and HCT15, which show epithelial characteristics, were 
exposed to low oxygen concentrations (0.5% O2) for 30 hours. DLD-1 and HCT15 
cells represent micro-satellite instable (MSI), whereas HT29 cells represent 
microsatellite stable (MSS) CRC lines (see also Table 5.1 for the main genetic 
features of the CRC lines used here).   
 
Table 5.1 TP53, APC, KRAS, BRAF, PIK3CA and microsatellite status of CRC cell lines. 
Origin Cell lines TP53 APC KRAS BRAF PIK3CA MSI status 
human 
DLD-1 MUT MUT MUT MUT MUT MSI 
HT29 MUT MUT WT MUT MUT MSS 
HCT15 MUT MUT MUT WT MUT MSI 
LoVo WT MUT MUT ? WT MSI 
SW480 MUT MUT MUT WT WT MSS 
SW620 MUT MUT MUT WT WT MSS 
HCT116 TP53
-/-
 KO WT MUT WT MUT MSI 
HCT116 TP53
+/+
 WT WT MUT WT MUT MSI 
RKO TP53
-/-
 KO WT WT MUT MUT MSI 
RKO TP53
+/+
 WT WT WT MUT MUT MSI 
SW48 TP53
-/-
 KO WT WT WT WT MSI 
SW48 TP53
+/+
 WT WT WT WT WT MSI 
murine CT26 WT WT MUT WT WT MSS 
 
  All lines displayed changes in morphology consistent with EMT, such as an 
increase in scattering, adoption of a spindle-like shape and decreased cell–cell 
contacts (Figure 5.1A). As expected, expression of HIF1A protein was induced by 
hypoxia (Figure 5.1B). In addition, hypoxia caused down-regulation of the epithelial 
marker E-Cadherin and up-regulation of mesenchymal markers, such as Vimentin 
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(VIM), SNAIL, FN and ZEB1 in DLD-1 cells (Figure 5.1B-C). As reported previously 
163, 194, STAT3 was activated by hypoxia, as evidenced by increased phosphorylation 
at residue S727. 
 
 
Figure 5.1 Hypoxia induces EMT. (A) Representative phase-contrast pictures, (B) Western 
blot and (C) qPCR analysis of DLD-1 cells exposed to 20% O2 or 0.5% O2 for 24 hours as 
indicated. Scale bar represents 25 µm. In panels C mean values ± SD (n = 3) are provided. (*) 
P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Later, DLD-1 cells were treated with cobalt chloride (CoCl2), a chemical inducer of 
HIF1A. Similar results were obtained after addition of CoCl2 (Figure 5.2). CoCl2 
treatment caused down-regulation of the epithelial marker E-Cadherin and 
up-regulation of mesenchymal markers, such as Vimentin (VIM), SNAIL, FN and 
ZEB1 in DLD-1 cells (Figure 5.2A-B). STAT3 was also activated by CoCl2 treatment, 
as evidenced by increased phosphorylation at residue S727 (Figure 5.2C). 
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Figure 5.2 Cobalt Chloride induces EMT. (A) Western blot, (B) qPCR and (C) Western blot 
analysis of the indicated proteins in DLD-1 cells treated with CoCl2 for the indicated periods. In 
panels B mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Hypoxia also resulted in the loss of E-cadherin from the outer membrane and the 
formation of F-actin stress-fibers in the cytoplasm (Figure 5.3). Both events represent 
hallmarks of EMT 195.  
 
Figure 5.3 Hypoxia induces EMT. Indirect immunofluorescence detections of the indicated 
proteins in DLD-1 cells exposed to 20% O2 or 0.5% O2 for 24 hours. Scale bar represents 25 
µm.  
 
  Hypoxia and CoCl2 treatment also enhanced invasion and migration of DLD-1 cells 
in a modified Boyden-chamber assay (Figure 5.4).  
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Figure 5.4 Hypoxia enhances invasion and migration. Relative invasion and migration of 
DLD-1 cells treated with cobalt chloride (40 ng/ml) (A) and hypoxia (B). mean values ± SD (n = 
3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Hypoxia-induced EMT, as well as invasion and migration, were mediated by 
activation of HIF1A in CRC cells, since treatment with HIF1A-specific siRNAs 
suppressed these processes (Figure 5.5). Therefore, the subsequent analyses on 
HIF1A mediated effects were focused.  
 
 
Figure 5.5 Hypoxia induces HIF1A-dependent EMT. (A) Western blot and (B) relative 
invasion and migration analyses in DLD-1 and HT29 cells transfected with indicated siRNA for 
24 hours and then cultured at 20% O2 or 0.5% O2 for 30 hours. In panels B mean values ± SD 
(n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
 
5.2 HIF1A directly represses miR-34a expression  
  I also noted that the expression of primary and mature miR-34a and primary 
miR-34b/c was repressed in a number of TP53-deficient, whereas they were induced 
in TP53-proficient CRC cell lines (Figure 5.6) indicating a role of p53 in this context 
which will be addressed later.  
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Figure 5.6 Differential expression of miR-34a and miR-34c in CRC cell lines in the 
response to hypoxia. (A) qPCR analysis of mature miR-34a expression in the indicated CRC 
cell lines at 0.5% O2 for 48 hours. (B) qPCR analysis of indicated mRNAs in DLD-1 cells 
treated with CoCl2 for the indicated periods. (C, D) qPCR analysis of indicated mRNAs and 
miRNAs in different cell lines kept at 20% O2 or 0.5% O2 for 48 hours. mean values ± SD (n = 3) 
are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
  Notably, inactivation of HIF1A by RNA interference prevented the down-regulation 
of pri-miR-34a (Figure 5.7), suggesting that HIF1A is directly represses miR-34a, 
which encodes a p53-inducible microRNA with tumor suppressive features 79, 156.  
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Figure 5.7 Hypoxia represses miR-34a via HIF1A. qPCR analysis of DLD-1 (A) and HT29 
(B) cells transfected with indicated siRNAs for 24 hours and then cultured at 20% O2 or 0.5% 
O2 for 30 hours. mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 
0.001. 
 
 
  Indeed, three conserved HIF1A binding sites with the sequence 5'-[A/G]CGTG-3') 
700 bp upstream of the miR-34a TSS (transcriptional start site) indicated as HRE 
(hypoxia-response element) 1-3 in Figure 5.8A were identified.  
 
 
Figure 5.8 Direct repression of miR-34a by HIF1A. (A) Map of the human miR-34a genomic 
region indicating conserved HIF1A binding sites. (B) ChIP analysis of HIF1A occupancy at 
human miR-34a and VEGF (positive control) promoters. 16q22 locus served as neg. control. 
(C) Dual-reporter assay after transfection of H1299 cells with the indicated reporters and 
constitutively active HIF1A encoding plasmids. (E) Dual reporter assay after transfection of 
H1299 cells with the indicated reporter constructs and treatment with cobalt chloride (40 ng/ml) 
for 48 hours. In panels B, C and D mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001.  
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  By chromatin immuno-precipitation (ChIP) HIF1A occupancy was detected at HRE2, 
but not at HRE1 and HRE3 in hypoxic DLD-1 cells (Figure 5.8B). HIF1A occupancy at 
the VEGF promoter served as a positive control. Furthermore, a reporter containing 
the miR-34a promoter region was repressed by ectopic expression of a constitutively 
active version of HIF1A and after treatment of cells with CoCl2 (Figure 5.8B-C). The 
repression by HIF1A was abolished by introduction of mutations into HRE2 (Figure 
5.8B).  
  As expected, the miR-34a reporter was induced by ectopic p53 expression (Figure 
5.9). Interestingly, increasing amounts of HIF1A encoding plasmids were sufficient to 
suppress activation of the reporter by p53. However, in the presence of equimolar 
amounts of p53 and HIF1A plasmids activation of miR-34a by p53 was dominant over 
its repression by HIF1A.  
 
 
Figure 5.9 Analysis of HIF1A/p53 antagonism. Dual reporter assay after transfection of 
H1299 cells with the indicated reporter constructs for 48 hours. 
 
 
  Interestingly, the induction of miR-34a in TP53-proficient CRC cell lines under 
hypoxia was not reversed by long-term exposure to low oxygen concentrations 
(Figure 5.10), indicating that increasing or sustained levels of hypoxia in 
TP53-proficient CRC cells are not sufficient to overcome the induction of miR-34a by 
p53. Taken together, these results show that miR-34a is directly repressed by HIF1A 
under hypoxic conditions in the absence of wild-type TP53.  
  Also miR-34b/c expression was down-regulated under hypoxic conditions in 
TP53-deficient and induced in TP53-proficient CRC cell lines (Figure 5.6D). Since the 
miR-34b/c promoter does not harbor a HRE (data not shown), miR-34b/c might be 
repressed by hypoxia via an indirect mechanism. As miR-34a is expressed at least 
hundred times higher than miR-34b/c in CRC lines and tumors 31, miR-34b/c was not 
analyzed further. 
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Figure 5.10 Effects of long-term hypoxia on pri-miR-34a expression. qPCR (upper panel) 
and Western blot (lower panel) analysis of human TP53-proficient CRC cell lines HCT116, 
RKO, LoVo and murine TP53-proficient CRC cell line CT26 exposed to 0.5% O2 for indicated 
time points. mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 
0.001. 
 
  Ectopic miR-34a expression suppressed the hypoxia-mediated induction of VIM, 
SNAIL, SLUG, and ZEB1, as well as the down-regulation of E-Cadherin in DLD-1 
cells (Figure 5.11A-B, upper panel). Moreover, ectopic miR-34a prevented 
hypoxia-induced invasion and migration of DLD-1 cells (Figure 5.11B, lower panel). 
 
 
Figure 5.11 Requirement of miR-34a down-regulation for EMT induced by hypoxia. (A) 
Flow cytometric determination of the frequency of DLD-1 cells by detection of eGFP 
expression. pRTR-pri-miR-34a expression was induced by addition of DOX for 48 hours. (B) 
qPCR (upper panel) and relative invasion and migration (lower panel) in 
DLD-1/pRTR-pri-miR-34a cells exposed to DOX for 2 days and/or then to 0.5% O2 for 30 hours. 
In panels B mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 
0.001.  
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  Similar results were obtained after treatment of DLD-1 cells with CoCl2 (Figure 
5.12). Therefore, down-regulation of miR-34a by HIF1A is required for 
hypoxia-induced EMT and invasion. 
 
 
Figure 5.12 Requirement of miR-34a down-regulation for EMT induced by CoCl2. qPCR 
analysis of the indicated mRNAs (A-B) and relative invasion and migration (C) in 
DLD-1/pRTR-pri-miR-34a cells after addition of DOX for 48 hours and subsequent treatment 
with CoCl2 for 24 hours. In panels B and C mean values ± SD (n = 3) are provided. (*) P < 0.05, 
(**) P < 0.01 and (***) P < 0.001. 
 
 
5.3 Inh3 is a direct miR-34a target  
  The hypoxia-mediated phosphorylation of STAT3 at S727 was blocked by 
HIF1A-specific siRNAs in DLD-1 and HT29 cells (Figure 5.13A). Moreover, 
down-regulation of STAT3 by siRNAs reversed the hypoxia-mediated repression of 
E-Cadherin and the up-regulation of SNAIL, as well as invasion and migration in 
DLD-1 and HT29 cells (Figure 5.13B-C). Therefore, HIF1A-mediated STAT3 
activation is required for the induction of EMT by hypoxia.  
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Figure 5.13 STAT3 mediates hypoxia-induced EMT. (A-B) Western blot and (C) relative 
invasion and migration analysis of DLD-1 and HT29 cells transfected with indicated siRNA for 
24 hours and then cultured at 20% O2 or 0.5% O2 for 30 hours. In panels C mean values ± SD 
(n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Since increased phosphorylation of STAT3 at S727 and down-regulation of 
miR-34a in DLD-1 cells exposed to hypoxia were observed (Figure 5.2.1B, and 
Figure 5.6A), whether these events may be causally related was asked. Indeed, 
STAT3pS727 was decreased after ectopic expression of miR-34a in SW480 cells, which 
is known to induce MET in these cells 48, whereas total levels of STAT3 protein 
remained unchanged (Figure 5.14). Therefore, I hypothesized that the induction of an 
uncharacterized miR-34a target is presumably involved in the activation of STAT3 by 
hypoxia.  
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Figure 5.14 miR-34a decreases the level of STAT3
pS727
. Western blot analysis in 
SW480/pRTR-pri-miR-34a cells after addition of DOX for the indicated periods. 
 
  To identify direct or indirect activators of STAT3 that are directly regulated by 
miR-34a I used the miRNA target prediction software miRWalk, which combines the 
results of 10 different algorithms (Table 5.2). Thereby, I found that the Inh3/PPP1R11, 
PPP1R8, PPP1R9A and PPP1R9B mRNAs, which encode protein phosphatase 
1/PP1 inhibitors, contain miR-34a seed-matching sites and therefore represent 
putative miR-34a targets (data not shown).  
 
Table 5.2 Predicted miR-34a seed-matching sites in human and murine Inh3 3’-UTRs. 
   
  Up-regulation of these PP1 inhibitors may lead to activation of STAT3 in cells that 
display miR-34a repression by hypoxia, since STAT3 is negatively regulated by PP1 
196, 197. Since ectopic expression of miR-34a resulted in the repression of Inh3 mRNA, 
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SW620 cells (Figure 5.15C and F). Also in the murine CRC cell line CT26 ectopic 
pre-miR-34a decreased Inh3 mRNA and INH3 protein expression (Figure 5.15G-H). 
 
Figure 5.15 Regulation of Inh3 expression by miR-34a. (A-B) qPCR and (C) Western blot 
analysis of indicated mRNAs in SW480 harboring pRTR-pri-miR-34a vectors after addition of 
DOX for the indicated periods. In (A) DOX was added for 48 hours. (D-E) qPCR and (F) 
Western blot analysis of indicated mRNAs in DLD-1 (D) and SW620 (E, F) harboring 
pRTR-pri-miR-34a vectors after addition of DOX for the indicated periods. In (A) DOX was 
added for 48 hours. (G) qPCR and (H) Western blot analysis of the indicated mRNAs in CT26 
cells transfected with pre-miR-34a for 48 hours. In panels A, B, D, E and G mean values ± SD 
(n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
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miR-34a seed-matching sites (SMS) (Figure 5.16A and Figure 5.17A). The human 
Inh3 3’-UTR reporters were both repressed after ectopic expression of miR-34a 
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whereas mutation of the human SMS-2 largely blocked repression by miR-34a. In 
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addition, the combined mutation of both SMS completely alleviated the repression by 
miR-34a. 
 
 
Figure 5.16 Human Inh3 is a direct target of miR-34a. (A) Schematic representation of Inh3 
3’-UTR indicating the miR-34 seed-matching sequences, phylogenetic conservation and 
mutagenesis. (B) Dual reporter assay after transfection of H1299 cells with the indicated 
miRNA oligonucleotides and human Inh3 3’-UTR reporter constructs. In panels B mean values 
± SD (n = 3) are provided. (*) P < 0.05; (**) P < 0.01 and (***) P < 0.001. 
 
 
  Similar results were obtained with murine Inh3 3’-UTR reporters (Figure 5.17). In 
detail, the murine Inh3 3’-UTR reporters were both repressed after ectopic expression 
of miR-34a (Figure 5.17). Mutation of the human SMS-1 only partially abrogated this 
repression, whereas mutation of the human SMS-2 largely blocked repression by 
miR-34a. In addition, the combined mutation of both SMS completely alleviated the 
repression by miR-34a.  
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Figure 5.17 Murine Inh3 is a direct target of miR-34a. (A) Schematic representation of the 
Inh3 3’-UTR indicating the miR-34 seed-matching sequences, their phylogenetic conservation 
and mutagenesis. (B) Dual reporter assay after co-transfection of H1299 cells with the 
indicated miRNA oligonucleotides and murine Inh3 3’-UTR reporter constructs. In panels B 
mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001.  
 
 
    Taken together, these results show that Inh3 is a direct and conserved target of 
miR-34.  
 
5.4 Direct induction of Inh3 by HIF1A  
  The degree of INH3 induction by hypoxia in different CRC cell lines (Figure 5.18) 
suggested that HIF1A might also directly induce Inh3 expression besides repressing 
its inhibitor miR-34a.  
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Figure 5.18 Hypoxia induces Inh3 expression. (A) Western blot analysis of the indicated 
proteins in DLD-1 cells cultured at 20% O2 or 0.5% O2 for the indicated periods. (B) qPCR 
analysis in DLD-1 cells cultured at 20% O2 or 0.5% O2 for 24 hours. (C, E, G) qPCR and 
Western blot (D and F) analysis in DLD-1 (C and D), HT29 (E and F) and SW480 (G) cells 
treated with CoCl2 for the indicated periods. In panels C, E and G mean values ± SD (n = 3) 
are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
  Furthermore, the induction of INH3 by hypoxia was prevented by treatment with 
HIF1A-specific siRNAs (Figure 5.19).  
 
 
Figure 5.19 Hypoxia induces INH3 via HIF1A. Western blot analysis of the indicated proteins 
in DLD-1 (A) and HT29 (B) cells transfected with indicated siRNA for 24 hours and then 
cultured at 20% O2 or 0.5% O2 for 30 hours. 
 
  Indeed, inspection of the Inh3 promoter revealed five HIF1A binding sites (Figure 
5.20A). HIF1A occupancy was detected by qChIP at HRE4 and HRE5, but not at 
HRE1-3 in hypoxic DLD-1 cells (Figure 5.20B).  
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Figure 5.20 Inh3 is a direct target of HIF1A. (A) Map of the human Inh3 genomic region with 
conserved HIF1A binding sites. (B) ChIP analysis of HIF1A occupancy at the human miR-34a 
promoter in DLD-1 cells at 20% O2 or 0.5% O2. In panels B mean values ± SD (n = 3) are 
provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  In line with these results, Inh3 expression showed a signficant, inverse correlation 
with miR-34a expression in 628 primary CRC tumors represented within the TCGA 
database (Figure 5.21).  
 
 
Figure 5.21 Correlative analysis of Inh3 and miR-34a expression. Correlative analysis of 
Inh3 and miR-34a expression in the samples of the TCGA collection of colon (COAD; n = 462) 
and rectal adenocarcinomas (READ; n = 166). Correlations were calculated using the 
Spearman coefficient. Matjaz Rokavec performed the analysis and generated the figure. 
 
 
  Moreover, PP1 interacts with INH3 in CRC cells was confirmed by 
co-immuno-precipitation (Figure 5.22), indicating that PP1 could indeed mediate the 
activating effect of INH3 on STAT3.  
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Figure 5.22 Co-immuno-precipitation (IP) analysis of INH3 and PP1. 
Co-immuno-precipitation (IP) analysis of endogenous INH3 and PP1 in SW480 (A) and 
SW620 (B) cells. (C) Co-immuno-precipitation (IP) analysis with the indicated antibodies (AB) 
of ectopic INH3 and PP1 in HEK293 cells. 
 
 
  Taken together, these results show that a coherent feed-forward regulation of Inh3 
by HIF1A and miR-34a mediates induction of INH3 by hypoxia leading to increased 
activity of STAT3 (Figure 5.23). 
 
 
 
 
Figure 5.23 Model of the coherent feed-forward regulation of INH3 and downstream 
effects. 
   
 
 
 
5.5 Induction of INH3 is required for hypoxia-induced EMT 
  In line with the results described above, the induction of Inh3 mRNA and protein by 
hypoxia was prevented by ectopic miR-34a expression (Figure 5.24).  
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Figure 5.24 Repression of miR-34a is required for induction of Inh3 by hypoxia. (A) 
qPCR (upper panel) and Western blot (lower panel) analysis of DLD-1 cells harboring a 
pRTR-pri-miR-34a vector exposed to DOX for 2 days and/or then at 0.5% O2 for 30 hours. (B) 
qPCR analysis of Inh3 mRNA expression in DLD-1/pRTR-pri-miR-34a cells treated with DOX 
for 2 days and then with CoCl2 for 1 day. mean values ± SD (n = 3) are provided. (*) P < 0.05, 
(**) P < 0.01 and (***) P < 0.001. 
 
 
  Furthermore, ectopic expression of Inh3 mRNA lacking miR-34a seed-matching 
sequences largely prevented inhibition of invasion and migration by ectopic miR-34a 
(Figure 5.25). Therefore, down-regulation of INH3 is required for inhibition of invasion 
and migration by miR-34a. 
 
 
Figure 5.25 Down-regulation of INH3 is required for inhibition of invasion and migration 
by miR-34a. Relative invasion and migration of SW480/pRTR-Inh3-VSV cells transfected with 
pre-miR-34a oligonucleotides for 5-6 hours and then treated with for 2 days. mean values ± 
SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
   
 
  In addition, down-regulation of INH3 by siRNAs prevented the induction of SNAIL 
and repression of E-cadherin by hypoxia (Figure 5.26A-C), as well as 
hypoxia-induced invasion and migration (Figure 5.26D-E) in DLD-1 and HT-29 cells. 
Thus, INH3 is a required mediator of hypoxia-induced EMT, migration and invasion in 
CRC cells.  
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Figure 5.26 INH3 is a required mediator of hypoxia-induced EMT, migration and 
invasion in CRC cells. (A-C) Western blot analysis of the indicated proteins in DLD-1 (A-B) 
and HT29 (C) cells transfected with indicated siRNA for 48 hours. (D-E) relative invasion and 
migration analysis of DLD-1 (D) and HT29 (E) cells transfected with indicated siRNAs for 24 
hours and then cultured at 20% O2 or 0.5% O2 for 30 hours. In panels D and E mean values ± 
SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  In the mesenchymal-like SW480 cells down-regulation of INH3 by siRNAs at 
standard cell culture conditions (20% O2) resulted in a decrease of VIM, SNAIL, 
STAT3pS727, and induction of E-cadherin (Figure 5.27A-B). Moreover, knockdown of 
Inh3 in SW480 cells decreased wound closure and attenuated cellular invasion and 
migration (Figure 5.27C-D). Similar results were obtained with mesenchymal-like 
SW620 (Figure 5.27A, B and D) and murine CT26 cells (Figure 5.27E-F). Therefore, 
elevated INH3 expression is also required for maintaining a mesenchymal-like state in 
human and murine CRC cell lines in the absence of hypoxia. 
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Figure 5.27 Elevated INH3 expression is required for maintaining a mesenchymal-like 
state. (A) Western blot, (B) qPCR and (D) relative invasion and migration analysis of SW480 
and SW620 cells transfected with indicated siRNA for 48 hours. (C) Wound healing assay of 
SW480 cells transfected with indicated siRNA for 48 hours. (E) Western blot and (F) qPCR 
analysis of CT26 cells transfected with indicated siRNA for 48 hours. In panels B, D and F 
mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
5.6 Ectopic expression of INH3 induces EMT, migration and invasion  
  After ectopic INH3 expression epithelial DLD-1 cells adopted a mesenchymal 
morphology, while no changes were observed after ectopic eGFP expression (Figure 
5.28).  
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Figure 5.28 Effects of ectopic INH3 and eGFP expression on DLD-1 cells. (A, B) Flow 
cytometric determination of the frequency of cells with inducible expression of eGFP in DLD-1 
cell pools harboring a (A) pRTR-Inh3-VSV or (B) a control pRTR vector after addition of DOX 
for 72 hours. (E) Representative phase-contrast pictures of DLD-1/pRTR-Inh3-VSV cells 
treated with or without DOX. Scale bars represents 25 µm. 
 
 
  Moreover, ectopic INH3 induced changes in protein expression consistent with 
EMT (Figure 5.29A). Furthermore, phosphorylation of STAT3 at S727 was induced 
by INH3 expression, while the total amount of STAT3 and phosphorylation of STAT3 
at Y705 were not affected (Figure 5.29A). Notably, ectopic INH3 promoted wound 
closure (Figure 5.29B), and enhanced cellular invasion and migration (Figure 5.29C).  
 
 
 
Figure 5.29 Ectopic expression of INH3 is sufficient for induction EMT in DLD1 cells. (A) 
Western blot analysis of indicated mRNAs in DLD-1/pRTR-Inh3-VSV cells treated with DOX 
for the indicated periods. (B) Wound healing assay and (C) relative invasion and migration of 
DLD-1/pRTR-Inh3-VSV cells treated with DOX. Scale bar represents 200 µm (G). In panels B 
and C, mean values ± SD (n = 3) are provided. (*) P < 0.05; (**) P < 0.01 and (***) P < 0.001.  
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DLD-1 cells ectopically expressing GFP displayed none of these effects (Figure 
5.30).  
 
 
Figure 5.30 Effects of ectopic eGFP expression on DLD-1 cells. (A) qPCR and (B) 
Western blot analysis of the indicated mRNAs in DLD-1 cells harboring a pRTR vector treated 
with DOX for the indicated periods. 
 
 
  Similar results were obtained in HT29 cells (Figure 5.31). After ectopic INH3 
expression epithelial HT29 cells adopted a mesenchymal morphology (Figure 5.31A). 
Moreover, ectopic INH3 induced changes in protein expression consistent with EMT 
(Figure 5.31B). Furthermore, phosphorylation of STAT3 at S727 was induced by 
INH3 expression, while the total amount of STAT3 was not affected (Figure 5.31B). 
Notably, ectopic INH3 enhanced cellular invasion and migration (Figure 5.31C).  
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Figure 5.31 Ectopic expression of INH3 is sufficient for induction of EMT HT-29 cells. (A) 
Representative phase-contrast pictures of HT29/pRTR-Inh3-VSV cells treated with or without 
DOX. Scale bar represents 25 µm. (B) Western blot analysis of indicated mRNAs in 
HT29/pRTR-Inh3-VSV cells treated with DOX for the indicated periods. (C) Relative invasion 
and migration of HT29/pRTR-Inh3-VSV cells treated with DOX. In panel C mean values ± SD 
(n = 3) are provided, (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Notably, siRNA-mediated down-regulation of STAT3 prevented the up-regulation of 
VIM and SNAIL and the down-regulation of E-cadherin (Figure 5.32A-B), as well as 
the enhancement of invasion and migration by ectopic INH3 in DLD-1 cells (Figure 
5.32C). 
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Figure 5.32 STAT3 is a mediator of INH3 function. (A) Western blot, (B) qPCR and (C) 
relative invasion and migration analysis of DLD-1/pRTR-Inh3-VSV cells transfected with 
indicated siRNAs for 24 hours. Subsequently DOX was added for 30 hours. In panels B and C 
mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
   
  Taken together, these results show that INH3 activation is sufficient to induce EMT, 
invasion and migration in a STAT3-dependent manner. 
 
5.7 INH3 mediates hypoxia-induced metastasis formation 
  We had previously observed that DLD-1 cells are unable to form lung metastases 
after tail-vein injection in NOD/SCID mice 31 . However, pretreatment of 
Luc-expressing DLD-1 cells with 0.5% O2 for 48 hours allowed lung metastasis 
formation as documented by non-invasive imaging of luciferase activity over a period 
of 7 weeks (Figure 5.33A-C). Moreover, siRNAs directed against Inh3 largely 
inhibited lung metastasis formation. Histological analysis of resected lungs confirmed 
that knockdown of INH3 resulted in a decreased number of metastatic tumor nodules 
(Figure 5.33D-F). Taken together, these results show that INH3 mediates 
hypoxia-induced metastases formation. 
invasion                     migration
- - +   +           - - +     +      siSTAT3
- +      - +           - +      - +      DOX                                                                              
*** ***
*** ***
5
4
3
2
1
0
Fo
ld
 c
h
an
ge
A B
C
DLD-1/pRTR-Inh3-VSV
DLD-1/pRTR-Inh3-VSV
DLD-1/pRTR-Inh3-VSV
- INH3 / VSV 
- STAT3
- VIM
- E-cadherin
- STAT3pS727
- SNAIL
- β-actin
- - +         +        siSTAT3
- +        + - DOX
1.00       2.25         0.93      1.08     STAT3pS727 / β-actin
1.00       0.83       0..27      0.33     STAT3 / β-actin Fo
ld
 c
h
an
ge
 [
m
R
N
A
] 2
1
0
**
* n.s.
** ** ** * *
CDH1                  VIM                   SNAIL                 SLUG 
sictrl. / -DOX
sictrl. / +DOX
siSTAT3 / -DOX
siSTAT3 / +DOX
  Results 
74 
 
 
 
Figure 5.33 Analysis of INH3 function in a xenograft lung-metastasis assay. (A) Western 
blot analysis of DLD-1 cells kept at 0.5% O2 for 24 hours and then transfected with control and 
Inh3-specific siRNAs for 24 hours. (B-F) DLD-1 cells were kept at 0.5% O2 for 24 hours and 
then transfected with control and Inh3-specific siRNAs for 24 hours, subsequently injected into 
the tail veins of immune-compromised NOD/SCID mice (n = 6), and followed by noninvasive 
bioluminescence imaging for 7 weeks. (B) Quantification of non-invasive imaging at the 
indicated time points. Bioluminescence signals are presented as ‘total flux'. (C) representative 
examples of bioluminescence imaging at the indicated time points, (D, left panels) 
representative examples of bioluminescence imaging of lungs 7 weeks after tail vein injection; 
(D, right panels) representative images of lungs, arrows indicate metastatic nodules; (E) 
representative examples of H & E stained lung sections. Scale bars represent 1mm (left 
panels), and 200 μm (right panels). (F) Quantification of metastatic tumor nodules in the lung 
per mouse 7 weeks after tail-vein injection. In panels B and F mean values ± SD (n = 6), in H 
mean values ± SD (n = 3) are provided. (*) P < 0.05; (**) P < 0.01 and (***) P < 0.001. Huihui Li 
performed the analysis and generated the figure (A, F). Matjaz Rokavec performed the 
analysis and generated the figure (B-C). Longchang Jiang performed the analysis and 
generated the figure (D-E). 
 
   
5.8 miR-34-deficiency increases INH3 expression in adenomas of ApcMin/+ mice  
  In order to obtain evidence for a conservation of the identified regulations at the 
organismal level, the expression of INH3 and HIF1A in intestinal tumors of 
miR-34a/b/c-deficient ApcMin/+ mice 80 were determined. The expression of INH3 and 
HIF1A largely co-localized in the epithelial tumor cells of adenomas in ApcMin/+ mice 
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proficient and deficient miR-34a/b/c, consistent with the direct regulation of Inh3 
expression by HIF1A described above (Figure 5.34A). INH3, HIF1A, VIM and also 
STAT3pS727 levels were elevated in most of the 6 miR-34a/b/c-deficient adenomas 
analyzed here (Figure 5.34B).  
 
 
Figure 5.34 Analysis of INH3 expression in adenomas of miR-34-deficient Apc
Min/+
 mice. 
(A) Representative examples of immunohistochemical detections of INH3 and HIF1A protein 
expression in serial sections of adenomas from miR-34ab/c
+/+
; Apc
Min/+
 and miR-34a/b/c
-/-
; 
Apc
Min/+
 mice. Scale bars represent 200 µm (1. and 3. row) and 100 µm (2. and 4. row). (n = 6 
per genotype). (B) Western blot analysis of indicated proteins in lysates prepared from tumors 
of miR-34a/b/c
+/+
; Apc
Min/+
 and miR-34ab/c
-/-
; Apc
Min/+
 mice (1 tumor/mice, n = 6 per genotype). 
Relative densitometric quantifications of the indicated proteins normalized to β-actin are 
indicated. Longchang Jiang provided Apc
Min/+
 tumor samples and Huihui Li performed the 
analysis and generated the figure. 
 
 
  Next the response of tumoroids derived from adenomas of ApcMin/+ mice to hypoxia 
were compared. Notably, Inh3 and VIM was up- and CDH1 mRNA down-regulated in 
miR-34a/b/c-deficient tumoroids, whereas miR-34a/b/c-proficient tumoroids showed 
the opposite regulations (Figure 5.35A). In addition, elevated INH3 protein 
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expression and induction of STAT3pS727 was consistently observed in 
miR-34a/b/c-deficient tumoroids exposed to hypoxia (Figure 5.35B).  
 
 
Figure 5.35 Analysis of INH3 expression in miR-34-deficient Apc
Min/+
 tumoroids. (A) 
qPCR and (B) Western blot analyses of tumoroids derived from adenomas of mice with the 
indicated genotypes exposed to 20% or 0.5% O2 for 48 hours as indicated. In panels A mean 
values ± SD (n = 6), in H mean values ± SD (n = 3) are provided. (*) P < 0.05; (**) P < 0.01 and 
(***) P < 0.001. Longchang Jiang provided Apc
Min/+
 tumor samples and Huihui Li performed the 
analysis and generated the figure. 
 
 
    Taken together, these results show that the regulations identified in human CRC 
lines also occur in vivo in a genetic mouse model of intestinal tumor formation and ex 
vivo in tumoroids derived from these adenomas.   
 
5.9 miR-34a mediates the repression of Inh3 by p53  
  Since the induction of MET is considered to be an important aspect of the tumor 
suppressive activity of p53 which is mediated, at least in part, by miR-34a, whether 
hypoxia-induced EMT is suppressed by p53 was determined. Indeed, the 
enhancement of invasion and migration observed after exposure to CoCl2 was 
abolished by ectopic expression of p53 (Figure 5.36A). Similarly, ectopic expression 
of p53 also inhibited cellular migration induced by CoCl2 as determined in a 
scratch-wound assay (Figure 5.36B). 
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Figure 5.36 p53 suppresses invasion and migration induced by CoCl2. (A) Relative 
invasion and migration and (B) wound healing assay of DLD-1/tTA-p53 cells treated with DOX 
for 2 days and/or subsequently with CoCl2 for 1 day. Scale bar represents 200 µm. mean 
values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Ectopic expression of p53 in SW480 cells resulted in repression of Inh3 mRNA and 
protein expression (Figure 5.37A-B) and decreased phosphorylation of STAT3pS727 
(Figure 5.37B). Ectopic expression of INH3 largely prevented the suppression of 
invasion and migration by p53 (Figure 5.37C), indicating that Inh3 repression by p53 
is required for these effects of p53. The repression of INH3 by p53 was alleviated by 
transfection of miR-34a-specific antagomirs (Figure 5.37D-E). Therefore, miR-34a 
mediates the repression of Inh3 by p53. 
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Figure 5.37 MiR-34a mediates the repression of Inh3 by p53. (A) qPCR and (B) Western 
blot analysis of INH3 expression in SW480/pRTR-p53-VSV cells after addition of DOX for the 
indicated periods. (C) Relative invasion and migration of SW480/pRTR-p53-VSV cells 
transfected with pCDNA3.1-Inh3-VSV for 5-6 hours and then treated with DOX for 48 hours. (D) 
Western blot analysis of SW480/pRTR-p53-VSV cells transfected with antago-miR-34a or 
antago-miR-negative control oligonucleotide for 24 hours and/or subsequently treated with 
DOX for 48 hours. (C) qPCR analysis of the indicated mRNAs in SW480/pRTR-p53-VSV cells 
transfected with antago-miR-34a or antago-miR-negative control oligonucleotide for 24 hours 
and/or treated with DOX for 48 hours. Antago-miR does not influence pri-miR-34a expression 
level but inhibits the function of the mature miR-34a 
198-200
. In panels A, C and E mean values ± 
SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
 
  Furthermore, treatment with the DNA damaging agent etoposide caused the 
down-regulation of INH3 protein expression in TP53+/+, but not in TP53-/- RKO cells 
(Figure 5.38A). Therefore, INH3 is also repressed after activation of endogenous p53 
by DNA damage. Furthermore, the repression of INH3 and also the decrease in 
STAT3pS727 mediated by p53 activation after DNA damage was prevented by 
miR-34a-specific antagomirs (Figure 5.38B).  
 
A B
SW480/pRTR-p53-VSV
D
SW480/pRTR-p53-VSV
SW480/pRTR-p53-VSV
- INH3
- p53 VSV
- α-tubulin
antago-miR-ctrl.
antago-miR-34a
DOX
+       +        - -
- - +      +
- +        - +   
SW480/pRTR-p53-VSV
C
- INH3
- STAT3pS727
- STAT3
- β-actin
0       24      48       72  hours + DOX   
- p53 VSV
1.00    0.99     0.80      0.75  STAT3pS727 / β-actin
1.00    1.18   1.16     1.16    STAT3/ β-actin
1.5
1.0
0.5
0.0
Fo
ld
 c
h
an
ge
****
invasion        migration
- +    +         - +    +     DOX
- - +       - - +     Inh3
** **
**1.5
1.0
0.5
0.0
0        24       48       72    hours
+DOX
Fo
ld
 c
h
an
ge
 [
In
h
3
]
SW480/pRTR-p53-VSV
E
25
20
15
10
5
0Fo
ld
 c
h
an
ge
 [
p
ri
-m
iR
-3
4
a
]
- - +     +     antago-miR-34a
- +    - +      DOX
+     +         - - antago-miR-ctrl.
  Results 
79 
 
 
Figure 5.38 MiR-34a mediates the repression of Inh3 by p53. (A) Western blot analysis of 
the indicated proteins in RKO TP53
+/+
 and RKO TP53
-/-
 cells after addition of etoposide (20 µM) 
for 48 hours. (B) Western blot analysis of the indicated proteins in RKO TP53
+/+
 cells 
transfected with antago-miR-34a or antago-miR-negative control oligonucleotide for 24 hours 
and/or subsequently treated with etoposide for 48 hours. 
 
 
  Moreover, the HIF1A-mediated induction of INH3 was prevented by ectopic p53 
expression (Figure 5.39).  
 
 
Figure 5.39 p53 suppresses Inh3 induced by CoCl2. qPCR analysis of the indicated mRNAs 
in DLD-1/tTA-p53 cells treated with DOX for 2 days and subsequently with CoCl2 for 1 day. 
mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Taken together, these results show that activation of p53 suppresses 
hypoxia-induced EMT and associated processes, such as enhanced invasion and 
migration, via miR-34a-mediated suppression of INH3. 
 
5.10 The p53/miR-34a/INH3/Stat3 pathway as a determinant of the hypoxic 
response  
  Next, the hypothesis that the differential regulation of miR-34a and Inh3 may 
determine the distinct cellular responses to hypoxia observed in TP53-positive and 
TP53-negative cells was made. Therefore, the response of three isogenic CRC cell 
lines differing in their TP53 status to hypoxia was analyzed.  
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  Under hypoxia, HCT116 TP53-/- cells adopted a mesenchymal morphology, while 
HCT116 TP53+/+ cells remained unchanged (Figure 5.40A). Furthermore, expression 
of miR-34a and pri-miR-34a was up-regulated and Inh3 was down-regulated under 
hypoxia in TP53+/+ cells, whereas TP53-/- cells showed the opposite regulations 
(Figure 5.40B). Moreover, SNAIL was repressed in TP53+/+ cells and induced in 
TP53-/- cells upon exposure to hypoxia (Figure 5.40C). 
 
 
Figure 5.40 TP53 status influences the differential expression of miR-34a/b/c and INH3 
after hypoxia in HCT116 cells. Representative phase-contrast pictures (A), qPCR (B) and 
Western blot (C) analysis of HCT116 TP53
-/-
 and TP53
+/+
 cells at 0.5% O2 for 48 hours. Scale 
bar represents 25 µm. In panels B mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001.  
 
 
  Similar results were obtained in TP53+/+ and TP53-/- RKO (Figure 5.41). Under 
hypoxia, RKO TP53-/- cells adopted a mesenchymal morphology, while HCT116 
TP53+/+ cells remained unchanged (Figure 5.41A). Furthermore, expression of 
miR-34a and pri-miR-34a was up-regulated and Inh3 was down-regulated under 
hypoxia in TP53+/+ cells, whereas TP53-/- cells showed the opposite regulations 
(Figure 5.41B). 
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Figure 5.40 TP53 status influences the differential expression of miR-34a/b/c and INH3 
after hypoxia in RKO cells. (A) Representative phase-contrast pictures, (B) qPCR and (C) 
Western blot analysis of HCT116 TP53
-/-
 and TP53
+/+
 cells kept at 0.5% O2 for 48 hours. Scale 
bar represents 25 µm. In panels B mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 
0.01 and (***) P < 0.001. 
 
 
  Similar results were also obtained in SW48 CRC cell lines (Figure 5.42). The 
expression of miR-34a and pri-miR-34a was up-regulated and Inh3 was 
down-regulated under hypoxia in TP53+/+ cells, whereas TP53-/- cells showed the 
opposite regulations (Figure 5.42). Moreover, SNAIL and VIM was repressed in 
TP53+/+ cells and induced in TP53-/- cells upon exposure to hypoxia (Figure 5.42). 
Therefore, these p53-dependent regulations are not restricted to a specific CRC cell 
line. 
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Figure 5.40 TP53 status influences the differential expression of miR-34a/b/c and INH3 
after hypoxia in SW48 cells. qPCR analysis of SW48 TP53
-/-
 and TP53
+/+
 cells kept at 0.5% 
O2 for 48 hours. mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 
0.001. 
    In addition, the analysis of the TP53-proficient murine CRC cell line CT26 
showed that the regulations mediated by wild-type TP53 are conserved between 
species (Figure 5.43). 
 
 
Figure 5.43 Hypoxia represses mesenchymal markers in the TP53-proficient murine 
CRC cell line CT26. (A) Western blot and (B) qPCR analysis of the indicated mRNAs in CT26 
cultured at 0.5% O2 for the indicated periods. In panels B mean values ± SD (n = 3) are 
provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
   
   The repression of INH3 and STAT3pS727 by hypoxia in HCT116 TP53+/+ cells was 
prevented by a miR-34a-specific antagomir (Figure 5.44A-B, left panel), 
demonstrating that miR-34a mediates the repression of INH3 and STAT3pS727 by 
hypoxia. Notably, hypoxia suppressed invasion and migration of TP53-proficient 
HCT116 cells (Figure 5.44B, right panel), which was prevented by miR-34a-specific 
antagomirs.  
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Figure 5.44 Inhibition of miR-34a prevents MET by hypoxia in TP53-proficient CRC 
HCT116 cell line. Western blot (A), qPCR (B, left panel) and relative invasion and migration 
(B, right panel) analysis of HCT116 TP53
+/+
 transfected with antago-miR-34a or 
antago-miR-negative control oligonucleotide for 48 hours and/or subsequently cultured at 20% 
O2 or 0.5% O2 for 30 hours. In panels B, C and E mean values ± SD (n = 3) are provided. (*) P 
< 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  Similar results were obtained in RKO TP53+/+ cells (Figure 5.45). Hypoxia 
repressed invasion and migration of TP53-proficient RKO cells, which was prevented 
by miR-34a-specific antagomirs.  
 
 
Figure 5.45 Inhibition of miR-34a prevents hypoxia-induced MET in the TP53-proficient 
RKO cells. qPCR ( left panel) and relative invasion and migration (right panel) analysis RKO 
TP53
+/+
 transfected with antago-miR-34a or antago-miR-negative control oligonucleotides for 
48 hours and subsequently cultured at 20% O2 or 0.5% O2 for 30 hours. mean values ± SD (n 
= 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
Similar results were also obtained in murine CRC cell line CT26 (Figure 5.46).  
 
HCT116 TP53+/+
A B
HCT116 TP53+/+
antago-miR-ctrl.
antago-miR-34a
0.5% O2
+        +      - -
- - +     +
- +         - +   
- p53
- INH3
- SNAIL
- STAT3pS727
- STAT3
- β-actin
1.00       0.87     1.07      1.19  STAT3pS727 / β-actin
1.00     1.13     1.13     1.14   STAT3 / β-actin
3
2
1
0F
o
ld
 c
h
an
ge
 [
m
R
N
A
]
SNAIL            CDH1            VIM
** **
**
* *
* **
** ***
invasion    migration
Fo
ld
 c
h
an
ge
1.5
1.0
0.5
0.0
antago-miR-ctrl. 20% O2
antago-miR-ctrl. 0.5% O2
antago-miR-34a   0.5% O2
RKO TP53+/+
** **
*** *
invasion    migration
Fo
ld
 c
h
an
ge
1.5
1.0
0.5
0.0
antago-miR-ctrl. 20% O2
antago-miR-ctrl. 0.5% O2
antago-miR-34a   0.5% O2
5
4
3
2
1
0F
o
ld
 c
h
an
ge
 [
m
R
N
A
]
SNAIL         CDH1            VIM
* *
* **** **
  Results 
84 
 
 
Figure 5.46 Inhibition of miR-34a prevents hypoxia-induced MET in the TP53-proficient 
murine CT26 cells. (A) Western blot and (B) qPCR analysis of CT26 transfected with 
antago-miR-34a or antago-miR-negative control oligonucleotide for 6 hours and subsequently 
cultured at 20% O2 or 0.5% O2 for 48 hours. In panels B mean values ± SD (n = 3) are 
provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
 
 
  In contrast, exposure of TP53-deficient HCT116 cells to hypoxia resulted in an 
increase in invasion and migration and signs of EMT (Figure 5.47). The repression of 
CDH1 on the mRNA and protein levels by hypoxia was abolished by treatment with 
pre-miR-34a oligonucleotide in HCT116 TP53-/- cells (Figure 5.47, left panel and 
middle panel). Also the induction of VIM (Figure 5.47, middle panel) and invasion and 
migration by hypoxia was abrogated by ectopic miR-34a (Figure 5.47, right panel).  
 
 
Figure 5.47 Ectopic miR-34a prevents EMT induced by hypoxia in TP53-deficient 
HCT116 cells. Western blot (left panel), qPCR (middle panel) and relative invasion and 
migration (right panel) analysis of HCT116 TP53
-/-
 transfected with pre-miR-34a for 48 hours 
and/or subsequently cultured under 20% O2 or 0.5% O2 for 30 hours. mean values ± SD (n = 3) 
are provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
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  Similar results were also obtained with RKO TP53-/- cells (Figure 5.48). The 
repression of CDH1 on the mRNA level by hypoxia was abolished by treatment with 
pre-miR-34a oligonucleotide in RKO TP53-/- cells (Figure 5.48, middle panel). Also 
the induction of VIM or SNAIL (Figure 5.48, left panel and middle panel) and invasion 
and migration by hypoxia was abrogated by ectopic miR-34a (Figure 5.48, right 
panel). Therefore, the repression of miR-34a by HIF1A is necessary for 
hypoxia-induced EMT and associated invasion and migration. 
 
 
Figure 5.48 Ectopic miR-34a prevents EMT induced by hypoxia in TP53-deficient RKO 
cells. Western blot (left panel) and qPCR (middle panel) and (right panel) relative invasion and 
migration analysis of RKO TP53
-/-
 cells transfected with pre-miR-34a for 48 hours and 
subsequently cultured at 20% O2 or 0.5% O2 for 30 hours. mean values ± SD (n = 3) are 
provided. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. 
   
 
  Taken together, the results show that the TP53 status and the resulting differential 
expression of miR-34a and INH3 control the response of CRC cells to hypoxia. 
 
5.11 Modulation of chemo-resistance by the p53/HIF1A/miR-34a/INH3/Stat3 
pathway  
  It has been reported that EMT confers chemo-resistance during tumor progression 
174. Therefore, whether the regulations identified here modulate the cellular response 
to 5-Fluoro-Uracil (5-FU), a chemotherapeutic agent commonly used for treating CRC 
201 was determined. For this TP53+/+ and TP53-/- HCT116 cells were compared in a 
colony-formation assay. Cells were cultured at 20% or 0.5% O2 for 48 hours and 
subsequently treated with either 5-FU or, as a control, DMSO for 3 days.  
  As previously shown 202, HCT116 TP53-/- cells were more resistant to 5-FU and 
therefore formed more colonies than TP53+/+ cells at 20% O2 (Figure 5.49A). In line 
with a protective effect of hypoxia-induced EMT, treatment with 5-FU at 0.5% O2 was 
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less inhibitory to the colony-formation of TP53-negative cells than treatment with 5-FU 
at 20% O2 (Figure 5.49A). Moreover, the relative resistance of HCT116 TP53
-/- cells 
to 5-FU at 0.5% O2 was abolished by knockdown of INH3 (Figure 5.49B). 
 
 
Figure 5.49 Analysis of hypoxia-mediated resistance to 5-FU and apoptosis in HCT116 
cells. (A-B) 500 cells were seeded per well into a six well plate and cultivated for 24 hours at 
20% O2, then exposed to 0.5% O2 for 48 hours, and subsequently treated with or without 5-FU 
for 72 hours. Subsequently cells were fixed and stained with crystal violet. Quantification of 
crystal violet staining (G, H, upper panel) and representative examples of crystal violet staining 
(G, H, lower panel). mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and (***) 
P < 0.001. 
 
 
 
  Similar results were obtained with the TP53+/+ and TP53-/- pair of RKO CRC cells 
(Figure 5.50).  
 
 
Figure 5.50 Analysis of hypoxia-mediated resistance to 5-FU and apoptosis in RKO cells. 
500 indicated cells were seeded per well into a six well plate and cultivated for 24 hours at 20% 
O2 and subsequently exposed to 0.5% O2 for 48 hours, and subsequently treated with or 
without 5-FU for 72 hours. Subsequently cells were fixed and stained with crystal violet. (upper 
panel) Quantification of crystal violet staining and (lower panel) representative examples of 
crystal violet staining. mean values ± SD (n = 3) are provided. (*) P < 0.05, (**) P < 0.01 and 
(***) P < 0.001.  
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  In line with results obtained in CRC lines in cell culture, miR-34a-/-; miR-34bc-/- 
tumoriods derived from adenomas of ApcMin/+ mice showed less apoptosis in response 
to 5-FU at 0.5% O2 than miR-34a
+/+; miR-34bc+/+ tumoroids (Figure 5.51).  
 
 
 
Figure 5.51 Analysis of hypoxia-mediated resistance to 5-FU and apoptosis in 
tumoriods derived from adenomas of Apc
Min/+
 mice. Quantification of cleaved-Caspase-3 
staining of tumoroids derived from adenomas of Apc
Min/+ 
mice proficient or deficient for 
miR-34a/b/c exposed to 20% O2 or 0.5% O2 for 48 hours and subsequently treated with or 
without 5-FU for 48 hours. For each condition n >= 11 tumoroids derived from 3 mice were 
analyzed per genotype. (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. Longchang Jiang 
performed the analysis and generated the figure. 
  Taken together, these results show that the p53/HIF1A/miR-34a/INH3/STAT3 
regulatory pathway mediates the differential response towards 5-FU and its 
modulation by hypoxia. 
 
 
5.12 INH3 expression in primary CRC samples 
  Next whether Inh3 expression is affected by the TP53 status in primary CRCs 
represented in the Cancer Genome Atlas (TCGA) database 106 was determined. 
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Figure 5.52 TP53 status influences Inh3 expression in primary CRCs. Associations of 
Inh3 expression with (A) the TP53 status in TCGA-COAD and TCGA-READ samples with 
known TP53 status (n = 419). Significance was calculated using Student’s t test.  (*) P < 0.05, 
(**) P < 0.01 and (***) P < 0.001. Matjaz Rokavec performed the analysis and generated the 
figure. 
 
 
  The 238 CRC samples with mutant TP53 displayed significantly elevated 
expression of Inh3 compared to 181 CRC samples expressing wild-type TP53 
(Figure 5.52 and Table 5.3). These findings were in line with the observations 
described above.  
 
Table 5.3 TP53 status of samples in the TCGA collection of human colon 
adenocarcinomas (n = 628).  
 
Number of cases Percentage 
TP53
wt
 181 43.19% 
TP53
mut
 238 56.81% 
TP53 status known 419 100.00% 
TP53 status unknown 209 N.A. 
Total 628 N.A. 
Matjaz Rokavec performed the analysis and generated the table. 
 
 
  In addition, primary CRCs with local metastasis to the lymph-nodes, showed 
significantly elevated expression of Inh3 compared to CRCs without local metastasis 
(Figure 5.53A). Moreover, primary tumors exhibiting distant metastases (M1) showed 
a trend towards increased expression of Inh3 (Figure 5.53B). 
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Figure 5.53 Association of Inh3 expression with local and distant metastases. 
Associations of Inh3 expression with (B) nodal and (C) distant metastasis in the combined 
TCGA-COAD and TCGA-READ database (n = 628). Significance was calculated using 
Student’s t test.  (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. Matjaz Rokavec performed the 
analysis and generated the figure. 
 
 
  In a matched case control cohort of primary colon cancers with (n = 42) and without 
(n =42) synchronous liver metastasis up-regulation of INH3 protein expression at the 
infiltrative tumor edge was significantly associated with liver metastasis (Figure 5.54A 
and Table 5.4).  
 
 
Table 5.4 INH3 expression and clinical variables. 
Characteristics Total 
Inh3 invasion front up 
P 
No Yes 
All patients 84 (100) 32 (38.1) 52 (61.9) 
 Age (y, Median 68) 
         < 68 40 (47.6) 15 (17.9) 25 (29.8) 0.91 
     ≥ 68 44 (52.4) 17 (20.2) 27 (32.1) 
 Gender 
         Male 40 (47.6) 16 (19.0) 24 (28.6) 0.73 
     Female 44 (52.4) 16 (19.0) 28 (33.3) 
 Tumor size (UICC) 
         T2 8 (9.5) 5 (6.0) 3 (3.6) 0.27 
     T3 62 (73.8) 21 (25.0) 41 (48.8) 
      T4 14 (16.7) 6 (7.1) 8 (9.5) 
 Nodal status 
         N0 37 (44.0) 18 (21.4) 19 (22.6) 0.08 
     N+ 47 (56.0) 14 (16.7) 33 (39.3) 
 Metastasis (Liver) 
         M0 42 (50.0) 23 (27.4) 19 (22.6) 0.002 
     M1 42 (50.0) 9 (10.7) 33 (39.3) 
 Tumor grade (WHO) 
         Low 28 (33.3) 8 (9.5) 20 (23.8) 0.2 
     High 56 (66.7) 24 (28.6) 32 (38.1) 
 Percent values are given in parentheses 
Human patient sample collection was stained by the diagnostics laboratory, Pathology Institute, 
LMU, Munich. David Horst performed the microscope evaluation and generated the table.  
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  Interestingly, HIF1A was shown to be up-regulated at the invasion front of CRCs 
indicating that these regions are hypoxic 203. Accordingly, elevated INH3 expression in  
infiltrative CRC cells that had undergone EMT, as evidenced by Laminin 5γ2 positivity, 
was associated with increased expression the hypoxia marker GLUT1 (Figure 
5.54B).  
 
 
 
Figure 5.54 INH3 expression at the invasion front of primary CRCs. (A) INH3 expression 
in primary colon cancer samples of 84 patients who underwent surgical tumor resection at the 
Ludwig-Maximilians-University, Munich between 1994 and 2005. Percentage values are given 
in parentheses. Data were analyzed using the χ
2
 test. (B) Examples of representative 
immunohistochemical detections. Scale bar represents 100 µm. Human patient sample 
collection was stained by the diagnostics laboratory, Pathology Institute, LMU, Munich (A-B). 
David Horst performed the microscope evaluation (A). Huihui Li generated the figure (A). 
David Horst took pictures and generated the figure (B).  
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  Moreover, the expression of INH3 protein at the infiltrative tumor edge showed a 
significantly negative correlation with the expression of miR-34a (Figure 5.55) which 
is consistent with the above mentioned analysis of the TCGA database (Figure 5.21). 
 
 
 
Figure 5.55 Correlative analysis of miR-34a and INH3 in primary CRCs. Correlative 
analysis of Inh3 and pri-miR-34a expression in primary colon cancer samples of 67 patients as 
in D. pri-miR-34a expression was determined previously 
204
. Significance was calculated using 
Student’s t test.  (*) P < 0.05, (**) P < 0.01 and (***) P < 0.001. Human patient sample 
collection was stained by the diagnostics laboratory, Pathology Institute, LMU, Munich. David 
Horst performed the microscope evaluation. Huihui Li generated the figure. 
 
 
The negative correlation between miR-34a and Inh3 was more pronounced in 
ascending colon, hepatic flexure, and rectum than in other regions of the large 
intestine (Figure 5.56).  
 
BA
INH3                           Laminin 5γ2                        GLUT1 
C
60
40
20
0N
u
m
b
e
r 
o
f 
p
at
ie
n
t 
sa
m
p
le
s 
not elevated
elevatd
19
23
33
9
M0        M1
p=0.002
INH3 at invasion front:
150
100
50
0R
e
la
ti
ve
 e
xp
re
ss
io
n
 o
f 
m
at
u
re
 m
iR
-3
4
a
**
not elevated    elevated
n = 67
INH3 at invasion front
  Results 
92 
 
 
Figure 5.56 Analysis of Inh3 and miR-34a expression in CRC samples within the TCGA 
collection. Analysis of Inh3 and miR-34a expression in (A) colon adenocarcinomas (COAD) 
of the indicated location and (B) rectal adenocarcinomas (READ) from the TCGA database. 
Correlations were calculated using the Spearman coefficient. Matjaz Rokavec performed the 
analysis and generated the figure. 
 
  Next, the levels of INH3, Laminin 5γ2, and Glut1 in paired primary and metastatic 
lesions from 17 patients was determined (Figure 5.57A). The elevated expression of 
INH3, Glut1, and Laminin 5γ2 at the infiltrative tumor edge of primary tumors was also 
found at the edge of matched metastases in the majority of patient samples (Figure 
5.57B).  
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Figure 5.57 INH3, Glut1 and Laminin 5γ2 protein expression in primary CRCs and 
metastases. (A) Examples of representative immunohistochemical detections of INH3, Glut1, 
and Laminin 5γ2 expression at the invasion front of primary colon tumors and matched 
metastases. Scale bar represents 100 µm. (B) Summary of INH3, Glut1, and Laminin 5γ2 
expression at the invasion front of primary colon tumors (P) and matched metastases (M) in 
individual patients. Human patient sample collection was stained by the diagnostics laboratory, 
Pathology Institute, LMU, Munich (A-B). David Horst performed the microscope evaluation 
(A-B). Huihui Li took the pictures (A), and Matjaz Rokavec performed the calculation and 
generated the figure (B). 
 
  Moreover, elevated expression of INH3 was significantly associated with elevated 
expression of Glut1 and Laminin 5γ2 at the edge of primary tumors and metastases 
(Figure 5.58). 
 
 
Figure 5.58 Correlative analysis of INH3 and Glut1 or Laminin 5γ2 protein expression in 
primary CRCs and metastases. (A) Association between expression of Inh3 and Glut1 at the 
invasion front of primary tumors and metastases. (B) Association between expression of INH3 
and Laminin 5γ2 at the invasion front of primary tumors and metastases. significance was 
calculated using the χ
2
 test. Not elev., not elevated; elev., elevated. Human patient sample 
collection was stained by the diagnostics laboratory, Pathology Institute, LMU, Munich. David 
Horst performed the microscope evaluation, and Matjaz Rokavec performed the calculation 
and generated the figure. 
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    In addition, expression of INH3, Glut1 and Laminin 5γ2 was similar in the bulk 
areas of primary tumors and matched metastases (Figure 5.59). 
  
 
 
Figure 5.59 Analysis of INH3, Glut1 and Laminin 5γ2 protein expression in the bulk 
areas of primary CRCs and metastases. Summary of INH3, Glut1, and Laminin 5γ2 
expression in the bulk of primary colon tumors (P) and matched metastases (M) in individual 
patients. Human patient sample collection was stained by the diagnostics laboratory, 
Pathology Institute, LMU, Munich. David Horst performed the microscope evaluation, and 
Matjaz Rokavec performed the calculation and generated the figure. 
 
 
  Taken together, the expression pattern of INH3 detected in patient derived tumor 
samples indicates that the regulatory circuit characterized in this study is also 
manifest at the invasion front of primary CRCs and metastases. 
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6. Discussion 
  The results presented in this thesis demonstrate that the decision between EMT or 
MET in response to hypoxia is mediated by a regulatory network involving HIF1A, p53, 
miR-34a, INH3, PP1 and STAT3 (Figure 6.1). Since we could detect these 
regulations in both MSS and MSI CRC cell lines and also found an inverse correlation 
between Inh3 and miR-34a in tumors derived from different sites of the large intestine, 
the identified pathway seems to apply to CRCs in general. In the absence of 
functional p53, HIF1A mediates repression of miR-34a, whereas in the presence of 
wild-type TP53 expression of miR-34a is induced under hypoxia. HIF1A, miR-34a and 
Inh3 form a coherent, feed-forward regulatory loop, wherein HIF1A represses 
miR-34a, which encodes a repressor of INH3 and also directly activates Inh3 
transcription. This type of dual regulation has been described for other transcription 
factor and miRNA pairs, and confers increased robustness to regulatory systems 205. 
The resulting induction of INH3 was necessary for hypoxia-induced EMT, invasion 
and migration, as well as hypoxia-mediated resistance towards 5-FU. Since 
inactivation of INH3 prevented hypoxia-induced formation of lung-metastases of 
xenografted CRC lines in mice, these regulations may ultimately affect metastases 
formation in human patients. In line with these results, INH3 was not only required for 
hypoxia-induced EMT but also sufficient for the induction of EMT. However, in 
TP53-proficient cells, hypoxia resulted in p53 activation, miR-34a induction and a 
miR-34a-mediated induction of MET and down-regulation of INH3. This response may 
contribute to the strong selection for loss of TP53 and miR-34a during tumor 
progression. In support of this conjecture, we determined a significant association 
between TP53 mutation and INH3 up-regulation in primary CRC. Furthermore, 
increased INH3 expression at the invasion front of primary CRCs was associated with 
metastasis. Interestingly, also the invasion fronts of metastasis showed elevated 
expression of INH3 suggesting that it may contribute to secondary metastasis 
formation.  
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Figure 6.1 Model of the antagonistic regulation of the miR-34a/INH3/STAT3 pathway by 
p53 and HIF1A. 
 
  Previously, Graeber et al. showed that hypoxia induces apoptosis in murine tumors 
with wild-type TP53 expression, whereas TP53-deficient tumors progress under 
hypoxic conditions 121. Our findings imply that the differential regulation of miR-34a in 
these two scenarios may explain, at least in part, the different cellular responses 
under these conditions: in p53-proficient cells the hypoxia-mediated activation of p53 
and subsequent induction of miR-34a was dominant over the repression of miR-34a 
by HIF1A, causing inhibition of EMT which is generally associated decreased cell 
survival. In p53-deficient cells, miR-34a was repressed by HIF1A promoting EMT, 
miR-34a
EMT
Inh3
tumor suppression
STAT3pS727
PP1
TP53+/+
tumor progression
metastasis
chemo-resistance
MET
TP53-/-tumor hypoxia
HIF-1α
miR-34a
p53
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which confers resistance to apoptosis and enhances migration and invasion. Certain 
factors provided by the tumor micro-environment are able to induce EMT in cells 
expressing wild-type TP53 (e.g. e.g. IL-6 and TGF-B 206-210). This is, at least in part, 
facilitated by the down-regulation of genes encoding MET-mediating miRNAs, which 
are inducible by p53 (such as the miR-34 and miR-200 family members). Here we 
show that hypoxia leads to repression of miR-34a by HIF1A selectively in 
TP53-negative cells. However, it is conceivable that also CRCs expressing wild-type 
TP53 may undergo EMT when exposed to hypoxia in combination with EMT-inducing 
ligands.   
  Here we studied the effect of 5-FU on CRC cell lines and murine, intestinal 
tumoroids. We observed a desensitization upon loss of TP53 or miR-34a/b/c that was 
enhanced under hypoxic conditions. In addition, the increased resistance was 
dependent on the up-regulation of INH3. Since 5-FU is commonly used to treat CRC 
these results may be clinically relevant. Others have shown that isogenic CRC cell 
lines with either wild-type or deleted TP53 do not respond uniformly to different 
chemotherapeutic drugs 202: e.g. in the case of etoposide CRC cells with wild-type 
TP53 were less sensitive than TP53-deficient CRC cells. Therefore, further analyses 
are necessary to evaluate the role of the mechanisms identified here in the cellular 
response to other chemotherapeutic agents.  
  Besides, we also analyzed the expression pattern of INH3, the hypoxia marker 
Glut1 and the EMT-marker Laminin 5γ2 from 17 paired primary and metastatic lesions. 
However, no significant increase or decrease of these three proteins in the main 
areas of the metastases was observed when compared with matched primary CRCs. 
Furthermore, at the invasion front of both primary and metastatic cases, we did again 
observe a consistent increase in the expression of these proteins when compared to 
the bulk areas of the tumors or metastases in approximately half of cases. This may 
because tumor cells are heterogeneous with mixed epithelial and mesenchymal traits 
in the primary and metastatic lesions. The online data, which analyzed the expression 
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profiles of 18 matched primary colorectal cancers and associated liver metastases 211, 
also showed no significant difference in the expression of Laminin 5y2, Inh3, GLUT1, 
and HIF1A mRNAs in the bulk tumor mass when compared to the matched 
metastasis as well. Moreover, there was also no difference in expression of 
EMT-associated mRNAs VIM, CDH1, SNAI, and SLUG between primary tumors and 
metastases 211.  
  Interestingly, elevated expression of INH3 was significantly associated with 
elevated expression of Glut1 and Laminin 5γ2 at the edge of primary tumors and 
metastases, indicating INH3 is associated with hypoxia-induced EMT in primary CRC 
and metastases. Moreover, the similar expression was observed in 17 paired primary 
and metastatic lesions, suggesting that INH3 may contribute to secondary metastasis 
formation. Therefore, the regulations, we initially detected in CRC cell lines, are also 
manifest at the invasion front of primary colorectal cancers and derived metastatic 
lesions. Elevated expression of EMT-TFs SNAIL, SLUG, ZEB1, ZEB2, and TWIST 
was found at the invasion front in different cancers 203, 212-216. Moreover, the 
expression of the EMT marker Vimentin at invasion front was also upregulated 217. 
Also downregulation of E-cadherin at invasion front was reported previously 218. Thus, 
the upregulation of INH3 at the invasion front indicates that INH3 may also be an 
important EMT regulator in vivo. Interestingly, it was previously shown that HIF1A is 
significantly up-regulated at the invasion front of CRCs indicating that these regions 
are hypoxic 203. Moreover, endogenous marker of hypoxia carbonic anhydrase 9 (CA9) 
was also found with high abundance at the invasion front of gastric cancers 219. We 
found that expression of another hypoxia marker GLTU1 was also elevated at 
invasion front. Altogether, elevated expression of INH3 at the invasion front was 
associated with markers of EMT and hypoxia, indicating that INH3 may be a new 
marker for hypoxia-induced EMT. 
  Here, we showed that p53/miR-34a regulates hypoxia-induced EMT via INH3. 
Indeed, the TCGA data showed that Inh3 expression was increased in mutant TP53 
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CRC samples and significantly inversely correlated with miR-34a expression in 
primary CRCs. Besides, In 67 of the cases analyzed by TMA for INH3 expression, we 
had previously determined the expression of mature miR-34a 204. The results showed 
that increased expression of INH3 protein at the infiltrative tumor edge with a 
significantly decreased expression of miR-34a and vice versa. Thus, the expression 
of INH3 protein and miR-34a negatively correlate in clinical samples. 
  We have shown that epigenetic silencing of miR-34a in primary tumors is 
associated with increased lymph node infiltration and metastasis in colon cancer 
patients 204. It is conceivable that the transient repression of miR-34a by hypoxia 
observed here is fixated over time by DNA hyper-methylation in its promoter region. 
The loss of miR-34a expression by epigenetic silencing subsequent to 
hypoxia-mediated repression might facilitate cancer cell survival and local invasion or 
migration. In addition, the silencing of miR-34a may itself contribute to the adaptation 
of tumor cells to the hypoxic tumor microenvironment, since miR-34a has many 
targets that would favor a survival under such circumstances, such as LDH-A and 
Survivin 182. 
  Tumor suppressor miRNAs represent an essential direction for new therapeutic 
investigation for their function during cancer progression. The repression of INH3 by 
miR-34 may be an essential component in the regulation of EMT under hypoxia. Our 
results suggest that inhibiting HIF1A, INH3 and/or STAT3 in combination with 
restoring miR-34a function may have therapeutic potential for the treatment of 
invasive colorectal cancers that display hypoxia. Targeting hypoxic tumor cells is one 
of the most attractive therapies for cancer treatment. Several approaches, including 
hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific 
targeting of HIF, or targeting pathways important for hypoxic cells, such as the mTOR 
and UPR pathways have been designed 220. Moreover, many pharmacological 
inhibitors that target STAT3 were reported 221. Re-expression of miR-34a caused to 
20% to 83% repression of tumor growth 82 without severe toxicity or unwanted 
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immune response 81-83. Intriguingly, in April 2013, MRX34, a liposome-based miR-34 
mimic, became the first cancer-targeted miRNA-based drug in phase I clinical trial in 
patients with advanced hepatocellular carcinoma 82, 84. Interestingly, a miR-34a 
restoration may also harness the patients’ immune system against tumors, since the T 
lymphocyte inhibitory molecule PD-L1, which is expressed at elevated levels on 
certain tumors, represents a miR-34a target 222, 223. As suggested by our results this 
may be especially relevant in tumors that are driven by hypoxia. Since the HIF1A 
pathway has been targeted by multiple approaches 110, a combination of HIF1A 
inactivation and miR-34a restoration may be feasible in order to prevent or inhibit 
hypoxia-driven formation of metastases.  
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7. Summary 
  In colorectal cancer (CRC), hypoxia causes resistance to therapy and promotes 
metastasis. Mutation of the tumor suppressor TP53 provides a selective advantage to 
cancer cells under conditions of hypoxia, but little is known about the mediators of this 
effect. 
  In this thesis I could show that the hypoxia inducible factor 1 alpha subunit (HIF1A) 
directly represses the MIR34A gene in TP53-defective CRC cells, whereas 
expression of MIR34A was induced in TP53-proficient CRC cells exposed to hypoxia. 
Down-regulation of MIR34A was required for hypoxia-induced epithelial to 
mesenchymal transition (EMT), invasion and migration, and activation of STAT3 in 
CRC cells. In this study the PPP1R11 (protein phosphatase 1 regulatory inhibitor 
subunit 11; INH3; HCGV; IPP3; HCG-V; TCTE5; TCTEX5; CFAP255), was identified 
and characterized as a target of MIR34A. PPP1R11 mediates phosphorylation 
(activation) of STAT3 by inhibiting protein phosphatase (PP1), so expression of 
MIR34A inhibited STAT3 activity in TP53-negative CRC cells. Ectopic expression of 
INH3 in CRC cells induced EMT, invasion, and migration, which all required STAT3. 
Increased expression of INH3 in TP53-negative CRC cells was required for 
hypoxia-induced EMT, invasion, migration, and chemo-resistance to 5-fluorouracil, as 
well as metastases of xenograft tumors to lungs of mice. Adenomas and derived 
tumoroids of ApcMin/+ mice with disruption miR34a, miR34b and miR34c expressed 
increased levels of INH3. Colorectal tumors from patients dispalyed increased levels 
of INH3 at areas of invasion, compared with other areas of the tumor. Increased INH3 
levels associated with TP53 mutations and metastasis to liver.  
  HIF1A represses, whereas p53 increases, expression of MIR34A in CRC cells. 
MIR34A reduces expression of INH3 to prevent activation of STAT3 and inhibit the 
EMT and metastasis. In the future strategies to target this pathway might be 
developed to inhibit CRC metastasis and overcome resistance to therapy associated 
with hypoxia.
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8. Zusammenfassung  
  Hypoxie verursacht Therapieresistenz und fördert die Metastasierung von 
kolorektalen Karzinomen (KRK). Unter hypoxischen Bedingungen verleiht die 
Mutation des Tumorsuppressorgens TP53 den Krebszellen einen selektiven Vorteil. 
Die Mediatoren dieses Effektes sind jedoch weitgehend unbekannt. 
  In der vorliegenden Arbeit konnte ich zeigen, dass unter Hypoxie der 
Hypoxie-induzierbare Faktor-1a (HIF1A) das MIR34A-Gen in TP53-defekten 
KRK-Zellen unterdrückt, während in TP53-kompetenten KRK-Zellen die Expression 
von MIR34A induziert wird. Die Herabregulierung von MIR34A in KRK-Zellen war für 
die Hypoxie-induzierte Epithelial-Mesenchymale-Transition (EMT), Invasion und 
Migration, sowie Aktivierung von STAT3 verantwortlich. In dieser Arbeit wurde die  
Protein Phosphatase 1 regulatorische Inhibitor Untereinheit 11 (PPP1R11; INH3; 
HCGV; IPP3; HCG-V; TCTE5; TCTEX5; CFAP255), welche einen Inhibitor der 
Protein Phosphatase 1 (PP1) kodiert, als eine durch MIR34A-regulierte mRNA  
identifiziert und charakterisiert. INH3 vermittelt die Phosphorylierung und damit 
Aktivierung des STAT3 Proteins durch Inhibition von PP1. Die Expression von 
MIR34A in TP53-negativen KRK-Zellen reduzierte daher die Aktivität von STAT3. Die 
ektopische Expression von INH3 in KRK-Zellen induzierte STAT3-abhängige EMT, 
Invasion und Migration. Die erhöhte Expression der INH3 in TP53-negativen 
CRC-Zellen war erforderlich für Hypoxie-induzierte EMT, Invasion, Migration und 
Chemo-Resistenz gegenüber 5-Fluorouracil, sowie für die Metastasierung von 
Xeno-transplantierten KRK-Zellen in Lungen von Mäusen. Adenome und abgeleitete 
Tumoroide von ApcMin/+ Mäusen mit Deletion von miR34a, miR34b und miR34c 
zeigten eine erhöhte INH3 Proteinexpression. Primäre KRKs von Patienten wiesen 
erhöhte INH3 Proteinexpression an der Invasionsfront im Vergleich zu anderen 
Bereichen des Tumors auf. Erhöhte INH3-Levels waren mit TP53-Mutationen und 
Lebermetastasen assoziiert. 
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  Insgesamt konnte gezeigt werden, dass die Expression von MIR34A in KRK-Zellen 
durch HIF1A inhibiert und durch p53 hingegen erhöht wird. MIR34A unterdrückt die 
Expression von INH3 und verhindert so die Aktivierung von STAT3 und hemmt EMT 
und Metastasierung. In der Zukunft könnten Strategien zur gezielten Beeinflussung 
dieses Signalwegs genutzt werden, um die Metastasierung von KRKs zu hemmen 
und die Hypoxie-induzierte Therapieresistenz beim KRK zu überwinden. 
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